Molecular Pathology of Skin Neoplasms of the Head and Neck.
BASAL CELL CARCINOMA
Epidemiology and Risk Factors
Basal cell carcinoma (BCC) is the most common cancer in white persons. Approximately 80% of the nonmelanoma skin cancers that are diagnosed annually in the United States--estimated at more than 2 million--are BCCs, with the remainder being mostly squamous cell carcinomas (SCCs); thus, their prevalence is approximately equal to that of all other cancers combined, reported at more than 1.5 million. (1-5) Worldwide annual incidence increases of 3% to 10% are estimated. (1) Basal cell carcinoma is slightly more common in men than in women, and sporadic BCC typically occurs after the fourth decade of life. (5-7) It predominantly affects patients with a light skin phenotype, especially with blue eyes, light or red hair, and easy freckling. (1,6)
The skin of the head and neck region is by far the most commonly affected site, with 70% to 80% of all BCCs occurring here. (8,9) This may be due in part to UV exposure, which is the predominant risk factor for BCC. (2,5,10) In contrast to SCC, intermittent strong exposure, such as from recreational activities and starting at a young age, appears to be a more important risk factor than chronic sun exposure. (2,11) Other risk factors include ionizing radiation (eg, in the head and neck area due to treatment of tinea capitis, lymphoma, or port-wine stains) and immunosuppression (transplant patients, hematolymphoid malignancies, human immunodeficiency virus [HIV] infection, and acquired immunodeficiency syndrome). (1,2,7)
Clinical and Histopathologic Features
Basal cell carcinoma can be an indolent or locally aggressive tumor, which, especially in the head and neck region, can cause significant morbidity, for example, due to invasion into cartilage and bone. This can lead to destruction of the nose, or invasion of the eye and nerves, and rarely, invasion into the brain. Overall recurrence rates are estimated to be 1% to 10%, with variation based on subtype and location but, in general, facial BCCs show higher local recurrence rates, especially those around the nose and ears. (12-15) This may be due to difficulty in achieving negative margins in these anatomic locations, and not surprisingly, there is an inverse correlation between distance to margins and recurrence. (16) However, metastases are extremely rare with an estimated 0.0028% to 0.55% frequency overall (reviewed in Gropper et al (17)). In contrast to SCC, there is no precursor lesion.
The main clinical BCC subtypes are nodular, micronodular, superficial, infiltrative (including morpheaform/sclerotic BCC), and fibroepithelioma of Pinkus. These subtypes also have distinct histologic correlates. The most common subtype (with an estimated 60%-75% overall) is the nodular (or nodulocystic) subtype, which is especially common in the head and neck area, with 89.6% of nodular BCCs occurring in this location. (9) Clinically, it presents as a translucent waxy papule with telangiectasias. It sometimes ulcerates, generating typical "rolled" borders. Histologically, this type consists of a nodular arrangement of lobules of tumor cells within a mucin-rich stroma (Figure 1, A). The cells have dark hyperchromatic nuclei with little cytoplasm and show a palisading arrangement in the periphery of the lobules. Often a retraction artifact is seen between tumor nests and stroma. Superficial BCC occurs less commonly in the head and neck area. In one study, (9) 39.9% of superficial BCCs were found in the head and neck region, while 45.9% were found on the trunk. Clinically, it often presents as an erythematous patch, and histologically the tumor lobules are attached to the epidermis with minimal extension into the dermis (Figure 1, B). Infiltrative BCC and its variations, morpheaform and sclerotic BCC, have a predilection for the head and neck region (eg, 94.8% of morpheaform BCCs were found in that region (9)). Clinically, it presents as a pale plaque with a scarlike appearance, and borders are difficult to discern. Histologically, it is composed of small, irregularly shaped narrow nests and strands of tumor cells without prominent palisading and retraction (Figure 1, C). This variant often shows deeply infiltrative growth and perineural invasion, and is associated with higher recurrence rates. (13-15,18) One study (19) found a 26.5% recurrence rate for infiltrative BCC, compared to 6.4% for nodular BCC. Metatypical BCC or basosquamous carcinoma is a controversial entity with different definitions, but overall is probably best described as a variation of infiltrative BCC with squamous differentiation, and is thought to possess greater metastatic potential. (10,20,21) Micronodular BCC shows smaller tumor nests than nodular BCC. Some (19,22,23) have suggested that this variant may behave more aggressively, possibly owing to deeper extension than the other subtypes. Fibroepithelioma of Pinkus is a polypoid variant that most often occurs on the back. In summary, BCCs in the head and neck region more often show an aggressive subtype than in other sites and may also behave more aggressively owing to anatomic limitations in achieving negative margins.
Hereditary Conditions and Molecular Pathology
Basal cell nevus syndrome or nevoid basal cell carcinoma syndrome (BCNS; Gorlin syndrome) is a rare autosomal, dominantly inherited condition with variable expressivity, although 30% to 50% of cases are due to spontaneous mutations. (2,24-27) Early on patients develop BCCs (up to thousands), usually during adolescence but sometimes as early as childhood, which can develop aggressive growth at a later stage. Typically, the BCCs initially develop on the central part of the face, followed by chest, back, and scalp. (26) Most of these patients typically also develop keratocystic odontogenic tumors of the jaw bones, which show destructive growth. Other characteristic findings are palmoplantar pits, cutaneous cysts, skeletal abnormalities, a characteristic coarse facial appearance, and, less commonly, ovarian and cardiac fibromas, medulloblastomas, meningiomas, rhabdomyosarcomas, and mesenteric cysts.
Bazex-Dupre-Christol syndrome is a rare genodermatosis with X-linked dominant inheritance, in which patients also develop BCCs from early in life, typically in the second to third decade. (28-31) Basal cell carcinomas occur especially on the face. Other adnexal lesions, such as basaloid follicular hamartomas and trichoepitheliomas, are also common. Other characteristic findings include follicular atrophoderma, which is characterized by widened follicular ostia forming depressions, especially on the extremities; hypotrichosis; and localized hypohidrosis. Rombo syndrome shows an autosomal dominant inheritance and produces a similar phenotype except that it is associated with vermiculate atrophoderma. The patients show no hypohidrosis. (32,33) Other inherited conditions associated with BCCs are linear unilateral basal cell nevus (34) and xeroderma pigmentosum (see "Squamous Cell Carcinoma").
Basal cell nevus syndrome is associated with mutations of the PTCH1 (patched 1) gene, the human homologue of the Drosophila patched gene, on chromosome band 9q22. (35-37) The protein product PTCH is part of the Hedgehog (HH) signaling pathway, which was originally described in embryonic development, and controls proliferation, differentiation, and apoptosis. PTCH is found in association with smoothened (SMO) within the cell membrane. Upon activation of HH signaling by binding of 1 of the 3 mammalian HH proteins (sonic hedgehog, Indian hedgehog, desert hedgehog) to PTCH, SMO is released and then activates interacting proteins such as suppressor of fused (SUFU), ultimately leading to activation of Gli (Gli family zinc finger) transcription factors Glil, Gli2, and Gli3, whose function is controlled by phosphorylation and proteolytic degradation (Figure 2). (2,38,39) Gli transcription factors then induce cell activation and proliferation through a variety of target genes, including Gli itself, transforming growth factor b, the antiapoptotic B-cell lymphoma 2 (Bcl-2) protein, or the platelet-derived growth factor receptor. (2,10)
Many different PTCH1 mutations (deletions, insertions, splice site alterations, nonsense or missense mutations) have been described in BCNS, but most often they lead to premature protein truncations. (40,41) These mutations render PTCH incapable of suppressing SMO. Thus, PTCH1 functions as a tumor suppressor gene. PTCH1 mutations appear randomly distributed throughout the gene without a distinct hot spot, although clustering is seen in the regions coding for the 2 large extracellular loops and the large intracellular loop. (40,42) Different types of mutations do not appear to correlate with the phenotype, that is, number and onset of BCCs. (41,43)
The yet-unidentified gene for Bazex-Dupre-Christol syndrome has been localized to chromosome region Xq24-27 30 and has very recently been narrowed to an 11.4-Mb interval on Xq25-27.1. (44) The underlying genetic defect in Rombo syndrome is still unknown.
Molecular Pathology of Sporadic BCCs
It is now clear that upregulated HH signaling is the most important molecular aberration also in sporadic BCC, and elevated Gli transcription factor activity, either due to PTCH1 inactivation or SMO activation, appears to be sufficient for carcinogenesis. (2,45,46) While earlier studies suggested lower numbers, (47,48) it appears that 67% to 90% of sporadic BCCs show mutations or loss of one or both PTCH1 alleles and 10% to 20% show mutations in SMO. (1,2,49-51) Most commonly, point mutations leading to a truncated protein and loss of heterozygosity (LOH) at 9q (which harbors PTCH1) are observed. (42,49,50,52) Absent or truncated PTCH1 protein is then unable to suppress SMO, leading to constitutively active HH signaling (Figure 2). SMO mutations render the molecule resistant to PTCH1 inactivation (Figure 2). (2,51) As a consequence of increased HH signaling, the transcription factor Gli1, which otherwise is found in the hair follicle, is often overexpressed in sporadic BCCs. (53) In addition to these truncating mutations, a Pro/Pro polymorphism in PTCH1 may be a risk factor for the development of more aggressive BCCs. (54,55)
Regarding the downstream consequences of upregulated HH signaling, Gli2 has been shown to induce G1-S cell cycle progression. (56) HH signaling has also been implicated in G2-M progression. (57,58) Candidate target genes for Gli transcription factors encode Gli itself (in a positive feedback loop), (59) PTCH1 (in a negative feedback loop), platelet-derived growth factor receptor, antiapoptotic Bcl-2, (56) proapoptotic CD95/FasL (which is negatively regulated by Gli), transforming growth factor [beta], and forkhead box protein E1 and forkhead box protein M1 transcription factors (the latter has been shown to cause more aggressive behavior in other tumors) (58) (also see Epstein (2) for overview). In addition, there appears to be synergism with phosphoinositide-3 kinase/Akt signaling and Wnt (Wingless and INT-1) signaling, (2,60) which is also supported by the observation of upregulated [beta]-catenin levels in sporadic BCCs. (61,62) Epidermal growth factor receptor-derived signals may also play a supportive role. (63)
The pivotal role of HH signaling in BCC pathogenesis has been supported by mouse models with genetic inactivation of various HH signaling components. For example, mice overexpressing sonic hedgehog, SMO with activating mutations, and Gli1 or Gli2, as well as mice with absent expression of PTCH1 (PTCH mice, which then develop a deletion at the wild-type allele), develop BCCs. (2,51,64-67) Interestingly, UV and ionizing radiation enhance growth and number of BCCs, as does p53 deletion. (2,64)
p53 overexpression is seen in BCC, especially in aggressive variants. (10) Forty percent to 65% of sporadic BCCs show mutations of the TP53 tumor suppressor gene, often with a "UV signature" that is comparable to the mutations seen in SCC (ie, dipyrimidine sites with a "CC" to "TT" or "C" to "T" mutation), underscoring the role of UV damage in BCC pathogenesis. (49,68,69) In contrast to other cancers, allelic loss of TP53 is rare in BCC. Biallelic point mutations are seen in 45% of cases. (69,70) TP53 mutations are also seen in p53-over-expressing clones in noncancerous skin of patients with BCC and SCC, which may represent an early precursor lesion at a molecular level. (70,71) Basal cell carcinomas are often morphologically heterogeneous (eg, infiltrative BCC arising in an otherwise nodular BCC). Interestingly, the histologically different areas within a BCC typically show a common TP53 mutation, but then form subclones with different additional TP53 mutations. (70) In addition, mouse models have shown that TP53 loss contributes to HH-induced tumorigenesis. (2,72) Interestingly, PTCH1 and SMO mutations are also most commonly UV-signature mutations. (58)
Molecular alterations in the tumor suppressors [p14.sup.ARF] (p14 alternate reading frame) and [p16.sup.INK4a] at the CDKN2A (cyclin-dependent kinase inhibitor 2A) locus have also been reported, but appear to occur only in a small fraction of BCCs. (73,74) Despite the higher risk for BCC in patients with xeroderma pigmentosum (XP), the role of DNA repair defects in sporadic BCC remains controversial. (2) Basal cell carcinoma, especially the less aggressive variants, shows less genomic instability than many other tumors, possibly contributing to its low propensity to metastasize. (2,10)
Melanin pigment forms small crescents overlying the nuclei of keratinocytes, especially in the basal layer, protecting them from the damaging effects of UV radiation. Melanocortin-1 receptor (MC1R) is highly polymorphic in white persons. Binding of [alpha]-melanocyte-stimulating hormone ([alpha]-MSH) to this receptor leads to production of photoprotective eumelanin ("brown/black" melanin) through cyclic adenosine monophosphate and microphthalmia transcription factor (MiTF). Certain defective MC1R variants are associated with a phenotype that shows red hair, fair skin, and predominance of nonphotoprotective pheomelanin ("red/yellow" melanin). (75,76) Individuals with these MC1R variants show an increased risk of melanoma, SCC, and BCC, even when differences in pigmentation are accounted for. (55,75,77,78) More recently, other determinants of pigmentation such as ASIP (agouti-signaling protein, an [alpha]-MSH antagonist at MC1R) and TYR (tyrosinase) have been identified in white persons, whose variants lead to a mildly increased risk of melanoma and BCC. (79) The same group reported other genetic risk factors for BCC that are not involved in skin pigmentation, such as variants of the keratin 5 and CDKN2A/B genes. (80)
Studies using HH inhibitors for therapy of BCCs have been published or are currently under way, for example, with the topical retinoid tazarotene, the plant alkaloid cyclopamine, and derivatives such as vismodegib (GDC-044), which target SMO. (2,58,81) Vismodegib has recently been shown to be effective in a subset of patients with metastatic or locally advanced BCC in a phase II trial, and in patients with BCNS, although adverse events in the latter study were common. (82,83) It has recently been approved in the United States for the treatment of locally advanced or metastatic BCC. Such novel approaches to treatment underscore the need to develop molecular diagnostics tools to guide therapy for BCC in the future.
SQUAMOUS CELL CARCINOMA
Cutaneous SCC is the second most common cutaneous malignancy after BCC, representing approximately 20% of the nonmelanoma skin cancers seen annually in the United States, now estimated at more than 2 million. (3,4,84) Squamous cell carcinoma typically occurs in older age groups and is more common in men than in women, and in fair-skinned individuals. (84) The head and neck region is the most commonly affected area, accounting for approximately 65% of all SCCs in lighter-skinned individuals. (1) Certain head and neck regions, such as the ears and lower lip, are more likely to develop SCC than BCC. (85) Often, SCCs in this region behave more aggressively, with SCCs of the central face, ears, lips, and scalp showing an elevated recurrence and metastasis risk. (85) In darker-skinned individuals, only 35% of cutaneous SCC occur in the head and neck region. (86,87)
Chronic UV damage (as opposed to acute intermittent UV damage, which has been implicated in BCC) is the most important etiologic factor for the development of cutaneous SCC and its precursor, actinic keratosis. (84) Thus, cumulative total lifetime exposure to sunlight is directly related to the risk for developing actinic keratoses and SCC. (88) White persons living in areas with higher UV exposure and lower latitude (11) are at increased risk for SCC.
UVB (280-320 nm) exposure, which produces free radicals leading to thymidine dimer formation in DNA, also affects DNA repair and cellular immunity. (89) Immunosuppression is also an important etiologic factor for SCC. For example, transplant patients undergoing immunosuppressive therapy are much more prone to develop cutaneous SCCs (up to 50% develop SCC after long-term therapy), which also behave more aggressively. (90-92) A higher incidence of SCCs, often associated with aggressive behavior, has also been reported in nontransplant patients receiving immunosuppressive therapy and in HIV-infected patients. (93-95)
Other etiologic factors for the development of SCCs are ionizing radiation, chronic inflammatory processes, human papillomavirus (HPV) infection (especially at anogenital sites, but in the setting of epidermodysplasia verruciformis, also in the face), and certain chemicals such as arsenic.
Clinically, SCC often presents as a firm, skin-colored or pink, hyperkeratotic or smooth, often slow-growing nodule or plaque, which can be ulcerated. (84) It often arises in or is associated with actinic keratoses. These are usually less than 1 cm, erythematous, hyperkeratotic, and often appear as multiple lesions, which are commonly seen on sun-exposed skin of fair-skinned, older individuals, especially the head and neck region, but also on hands and forearms. The lifetime risk for progression of actinic keratoses to invasive SCC has been estimated to be 8%. (96) Squamous cell carcinoma in situ often has an "eczematous" clinical appearance with erythematous, often scaly and/or crusted, patches or plaques. Squamous cell carcinoma can also be associated with many inflammatory or other skin lesions. In the head and neck region, acne conglobata, vitiligo, burn scars, or lupus vulgaris (a form of cutaneous tuberculosis) may play a role. (7)
Keratoacanthoma typically occurs at sun-exposed sites, especially on the face, shows rapid growth, and has the potential for spontaneous regression. (84) However, there are reports of some cases that have behaved aggressively. Clinically, it typically appears as a dome-shaped papule or nodule with a craterlike center plugged with keratin.
Histologic Features and Immunohistochemistry
Invasive SCC often shows an epidermal origin with adjacent squamous dysplasia or in situ carcinoma. Well-differentiated SCCs are easily recognizable as such, with nests of eosinophilic, often keratinizing, squamous cells with intercellular bridges (Figure 3). Nuclear atypia can be minimal. Moderately differentiated SCCs show more atypia and mitoses, and keratinization is less pronounced, while poorly differentiated tumors are sometimes difficult to recognize as SCCs owing to absent or very limited keratinization and intercellular bridges. Immunohistochemistry with antibodies against keratins (especially against high-molecular-weight keratins or broad-spectrum anti-keratin antibodies) and p63 can help with the diagnosis of poorly differentiated tumors, although positivity can be focal and sometimes a panel of antibodies needs to be used to demonstrate squamous origin. Spindle cell SCC more commonly is found in sun-exposed areas, such as the head and neck region, and may resemble sarcoma histologically, requiring immunohistochemical confirmation in many cases.
Actinic keratoses are dysplastic lesions that show varying degrees of cytologic atypia in epidermal keratinocytes, with overlying hyperkeratosis or parakeratosis with retained nuclei in the corneal layer (Figure 3). If the dysplastic epithelium encompasses the full thickness of the epidermis, a diagnosis of SCC in situ is made, although both lesions are part of the same spectrum.
Invasive cutaneous SCCs show an overall recurrence risk of 3.7% to 10.9% and a metastasis rate of up to 3.3%. (97,98) Proposed risk factors for metastasis and recurrence are immunosuppression, location, lymph node status, poor differentiation, perineural invasion, and lesions arising in scars, burns, chronic ulcers, and areas of radiation. With regard to location, SCCs of the lip appear to behave more aggressively (as do penile and scrotal SCCs), with recurrence and metastasis rates greater than 10%. (98) Lesions measuring greater than 2 cm have a 3-fold risk of metastasis and a 2-fold risk of recurrence. (88,98) However, depth of invasion and tumor thickness also are important predictors of metastasis. (99) The importance of tumor thickness has been supported by a recent prospective study that included 653 patients during a median follow-up time of 43 months. (100) In this study, multivariate analysis showed that tumor thickness is the most important independent predictive parameter of metastasis with a hazard ratio of 4.79.
Keratoacanthoma histologically shows features of very well-differentiated SCC. In addition, it is characterized by its symmetric and crateriform architecture with the central keratin plug, and cells have a characteristic glassy pale eosinophilic cytoplasm usually with only mild cytologic atypia.
Hereditary Conditions and Molecular Pathology
Xeroderma pigmentosum is an autosomal recessive condition that is characterized by marked photosensitivity with the development of hyperpigmented and hypopigmented lesions, atrophy, xerosis (dry skin), telangiectasia (dilated vessels), and actinic keratoses, especially on sunexposed skin. (101) These patients show a markedly elevated risk (approximately 1000-fold) for the development of skin cancers, including SCC, BCC, and melanoma, which often develop in childhood (median age, 8 years). (102,103) The head and neck region is predominantly affected with 97% of SCCs and BCCs occurring at this site. (103,104) Other manifestations are internal malignancies, and ocular and neurologic, such as due to progressive neurodegeneration in certain subtypes. (102,103,105)
Oculocutaneous albinism is another hereditary condition leading to increased susceptibility for the development of SCCs, BCCs and, rarely, melanoma. (106) In this heterogeneous group of genetic abnormalities there is absence or decreased amounts of melanin pigment in skin, hair, and eyes. Depending on the subtype, patients show diminished skin coloration from brown to completely white. Histologically, normal numbers of melanocytes with a decrease or absence of melanin are seen.
Epidermodysplasia verruciformis is a rare autosomal recessive condition characterized by decreased cell-mediated immunity, which leads to warts induced by a group of HPV types, especially HPV 3, 5, and 8, some of which are often not commonly seen in warts in otherwise healthy individuals. Up to 30% of those patients develop SCCs, especially at sun-exposed sites, such as the forehead and ears, starting in young adulthood. (107) Histologically, the lesions of epidermodysplasia verruciformis show epidermal hyperplasia with hyperkeratosis or parakeratosis and the keratinocytes have a characteristic grey cytoplasm, especially in the granular cell layer. Some lesions display atypia amounting to in situ carcinoma and, ultimately, invasive SCC. However, the histopathologic picture is relatively nonspecific and HPV typing may be helpful in establishing a more definitive diagnosis.
Patients with XP show various defects in DNA nucleotide excision repair mechanisms upon UV-induced damage. (108,109) As mentioned above, UV damage is characterized by the formation of photoproducts such as cyclobutane pyrimidine dimers or pyrimidine(6,4)pyrimidone photoproducts, which may then lead to mutant gene expression, cell transformation, and tumor development. (89) In healthy individuals, the nucleotide excision repair mechanism, which consists of approximately 40 gene products, including endonucleases and exonucleases, leads to removal of a wide range of such lesions. (102) Xeroderma pigmentosum is a heterogeneous disease consisting of at least 7 "complementation groups," as determined by thymidine uptake of fibroblast cultures from patients as a measure of DNA repair activity. These differ in clinical phenotype and severity. The underlying genes for these groups are now known and correspond to different repair genes (XPA to XPG). For example, the XPA group, a common variant that produces a very severe phenotype, is the result of mutations of the XPA gene on 9q34.1. The XPA gene product is a zinc finger protein involved in verification of DNA damage through binding to DNA damaged by photoproduct formation. (110,111) Affected genes in other groups are proteins involved in DNA damage detection (XPC, XPE); DNA helicases, which open damaged DNA (XPB, XPD); or endonucleases involved in excision of damaged DNA sequences (XPF, XPG). (108,109) Approximately 10% to 20% of patients with XP do not show defects of the nucleotide excision repair mechanism. These XP variants show defective bypass replication of damaged DNA, for example, with pyrimidine dimers, due to polymerase g mutations. (112,113)
Oculocutaneous albinism (OCA) is a heterogeneous group of disorders with different defects of melanin synthesis pathways, most often with autosomal recessive inheritance. (106) In the United States, affected individuals are often compound heterozygotes, with a different mutation present in each affected allele. The most common types are OCA types IA and II. In OCA type IA, different mutations (single base, frameshift, missense, nonsense) in the tyrosine gene at 11q14-21 lead to complete absence of its enzymatic activity, essentially shutting down melanin synthesis. (114,115) In type II OCA, tyrosinase activity is unaffected, and mutations in the P gene on 15q11-12 are observed, producing a milder phenotype. (116,117) The function of the P gene is not well characterized, but it appears to be involved in regulation of melanosomal pH and tyrosinase processing and transport. (118,119) Melanocortin-1 receptor mutations appear to have a modifying effect on type II OCA phenotype. (120) Mutations in the TYRP1 gene, which encodes tyrosinase-related protein-1, and is involved in eumelanin production, are seen in type III OCA. (121) Syndromic forms of albinism such as Chediak-Higashi syndrome or Griscelli syndrome show different genetic defects (for an overview see Scheinfeld (122)).
The underlying genetic defect for Epidermodysplasia verruciformis is not yet well characterized. Susceptibility loci at 2p21-24 and 17q25 have been described, with 2 candidate genes adjacent to 17q25 (EVER1/TMC6 and EVER2/TMC8), which are predicted to code for integral membrane proteins in the endoplasmic reticulum. (123,124)
Molecular Pathology of Sporadic SCCs
The TP53 gene is a critical tumor suppressor gene that regulates cell cycle progression, DNA repair, and apoptotic cell death. (125,126) p53 molecules form a tetramer, such that mutated p53 exerts a dominant-negative effect upon oligomerization with wild-type p53. The TP53 gene in cutaneous SCC often shows a characteristic UV signature with "C" to "T" or "CC" to "TT" mutations at dipyrimidine sites. (127-130) These findings have been supported by the observation that p53-deficient mice develop UV-induced SCCs after relatively short UV exposure, underscoring the pivotal role of UV-induced damage in the development of cutaneous SCC. (131) Other UV-induced changes, such as single-strand DNA breaks or formation of purine photoproducts, are also seen. (89)
Interestingly, p53 overexpression (as an indicator of mutated p53) is already seen in actinic keratoses and clinically nonlesional sun-damaged skin, suggesting that p53 alterations are early events in carcinogenesis, and that there is a field effect with molecular abnormalities in surrounding sun-damaged skin. (130,132,133) Upon chronic UV exposure, these clones of p53 mutant cells are believed to expand owing to their selective proliferative advantage and resistance to apoptosis when compared to surrounding normal keratinocytes. (134-136)
Clonal chromosomal abnormalities and LOH at 9p, 9q, 13q, 17p, and 17q are seen in early lesions such as actinic keratoses. (137) In addition, activating UV-induced mutations at codons 12, 13, and 61 of the HRAS (Harvey rat sarcoma) and KRAS (Kirsten rat sarcoma) proto-oncogenes, as well as alterations in MYC, have been reported in cutaneous SCC and UV-irradiated keratinocytes. (138-143) More recent data have estimated that RAS mutations occur in 21% of SCCs, with HRAS mutations being the most common, followed by NRAS (neuroblastoma ras viral oncogene homolog) and KRAS. (144) HRAS mutations are also commonly seen in patients with SCC developing upon BRAF (v-raf murine sarcoma viral oncogene homolog B1) inhibitor therapy in melanoma. (145)
In addition, increased levels or activation of epidermal growth factor receptor, Src (sarcoma) family tyrosine kinases, v-myc myelocytomatosis viral oncogene homolog (Myc), and activating transcription factor 1 have been seen as early as in actinic keratosis. (146) There is more evidence for dysregulation of intracellular tyrosine and serine-threonine kinases in SCC. Src family kinases, such as Fyn, often show elevated expression levels, along with decreased expression levels of their negative regulator Srcasm in SCC. (146,147) Protein kinase C8 expression, a mediator of UV-induced apoptosis, is downregulated in SCC.
As mentioned above, cutaneous SCC is often found associated with actinic keratoses. Interestingly, LOH at CDKN2A, encoding the tumor suppressors [p16.sup.INK4a] (a cyclin-dependent kinase inhibitor) and [p14.sup.ARF] (a p53 activator), is rarely seen in actinic keratosis but more commonly in invasive SCC, suggesting a role in tumor progression. (148,149) Mutation and decreased levels of I[kappa]B kinase [alpha], an important upstream regulator of the nuclear factor [kappa]B (NF-[kappa]B) transcription factor, have been observed in SCC, suggesting it can act as a tumor suppressor in this context. (150) In addition, sun sensitivity, as determined largely by skin pigmentation through MC1R polymorphisms, is a major determinant of an individual's risk for the development of SCC. (75) Sun sensitivity, as measured by skin cancer rates, differs more than 100-fold between individuals with different degrees of skin pigmentation.
Despite intensive research, no major recurrent driver mutations have yet been defined in SCC. A recent study (151) suggests a role for NOTCH1 and NOTCH2 mutations. The Notch signaling pathway regulates many aspects of development and tissue renewal. Ligand binding to the extracellular domain of Notch on the cell surface induces a series of cleavage events, which ultimately lead to nuclear translocation of the intracellular domain of Notch. Notch then forms a transcriptional activation complex with additional molecules such as RBPJ/CSL and coactivators of the mastermind-like (MAML) family. (152) Activating Notch mutations have been found in certain hematologic malignancies, but increasing evidence points toward a role for Notch as a tumor suppressor in SCC. (153-155) Recently, NOTCH mutations (many of them predicted to be inactivating or truncating) were found in a subset of SCCs at mucosal head and neck sites. (156,157) Shortly thereafter, truncating or inactivating NOTCH1 or NOTCH2 mutations were also found in most cutaneous SCCs (as well as a subset of lung SCCs), suggesting a similar tumor suppressor role for Notch in these neoplasms. (151)
Keratoacanthoma is a clonal neoplasm that can show complex cytogenetic abnormalities such as trisomy 7; gains on 8q, 1p, and 9q; and losses at 3p, 9p, 19p, and 19q. (158,159) However, when compared to conventional SCC, genomic aberrations appear to be less common in keratoacanthoma (37.1% versus 83.7%). While loss of 9p was seen more frequently in a recent study, (160) loss of 4p and gains of 1p, 14q, 16q, and 20q were more frequently seen in conventional SCC.
Atypical fibroxanthoma (AFX) is a rare neoplasm that shows worrisome clinical and histologic features, but typically carries a good prognosis. (161-164) It has a relatively low tendency for local recurrence (approximately 5%-10%), and metastases occur only in exceptional cases, although questions about proper classification of metastatic lesions remain. (163,165-168) It presents on sun-damaged skin of the elderly with a male predominance and a mean age above 70 years, most often in the head and neck region, as a fast-growing, small papule or nodule. (161,163)
Histologically, it is limited to the dermis without significant subcutaneous extension and is often polypoid with an epidermal collarette. The features are reminiscent of a pleomorphic sarcoma with a mixture of spindle, epithelioid, and giant cells, which show marked pleomorphism, often with bizarre forms, prominent nuclear atypia, and high mitotic activity, including atypical mitoses (Figure 5). However, lymphovascular or perineural invasion, deep subcutaneous extension, and necrosis are not seen. If present in a lesion with features of AFX, these indicate more aggressive behavior with increased likelihood of local recurrence or metastasis, according to a recent series. (169) Thus, lesions that exhibit these features with an otherwise AFX-like morphology are best termed pleomorphic dermal sarcoma. (169) Occasionally, AFX can be composed of less atypical-appearing, somewhat monomorphic spindle cells. Typically, the surrounding skin shows pronounced actinic changes with solar elastosis, telangiectasia, and sometimes actinic keratoses.
It is likely that this neoplasm is derived from a fibroblastic or myofibroblastic lineage. There are no specific positive immunohistochemical markers to identify AFX; thus, the diagnosis is one of exclusion. Staining with CD68 and CD10 is often positive, but these markers are not specific. A panel of immunostains with antibodies against cytokeratins, smooth muscle, and melanocytic antigens should be performed to rule out SCC (especially of the spindle-cell type), sarcoma, and melanoma, all of which carry a significantly worse prognosis. Recently, p63 has been proposed as an additional marker to rule out SCC, since spindle cell SCC often shows only focal and/or weak positivity for select keratins. In 2 studies, (170,171) spindle cell SCC was found to be positive for p63, while AFX was negative in 1 study with 2 cases positive in the other study.
Atypical fibroxanthoma is thought to be a predominantly UV-induced tumor, although irradiation and immunosuppression, for example, in organ transplant patients, are also thought to play a role. (163) The predominant role of UV-induced damage in the development of AFX is supported by the observation of UV-induced photoproducts and p53 mutations with the characteristic UV signature ("C to T" transitions), and also "C to G" transitions, at dipyrimidine sites. (172,173) The presence of AFX in children with xeroderma pigmentosum, a condition characterized by deficient nucleotide excision repair and UV-induced tumors early in life (see "Squamous Cell Carcinoma" section), further supports a UV-induced pathogenesis. (174-176) Interestingly, mutations in HRAS, KRAS, and NRAS proto-oncogenes were not seen in AFX, when compared to so-called malignant fibrous histiocytoma (undifferentiated pleomorphic sarcoma). (173) Comparative genomic hybridization showed that copy number losses at 9p and 13q are commonly seen in approximately half of undifferentiated pleomorphic sarcomas and AFX alike, while other alterations, such as gains at 4q, 5p, 7q, 11p, and 12p, are only seen in undifferentiated pleomorphic sarcoma, with gains being unusual in AFX (only 9p gains were seen). (177) These findings suggest at least a partially different molecular pathogenesis between those entities.
MERKEL CELL CARCINOMA Background
Merkel cell carcinoma (MCC; neuroendocrine carcinoma of the skin) is a rare tumor, but its incidence has rapidly increased in recent decades from 0.15 per 100 000 in 1986 to 0.44 per 100 000 in 2001. (178) It predominantly affects white patients older than 50 years with a mean age between 70 and 76 years. (179-181) Most commonly, it affects the sun-damaged skin of the head and neck region (approximately 50% of cases), followed by the extremities. (179-182) It presents as a firm, rapidly growing, usually rather small, red/pink and sometimes violaceous nodule (often less than 2 cm) with no specific clinical features. (180,182,183) The prognosis is poor owing to a high rate of regional lymph node and distant metastases. However, recent Surveillance, Epidemiology and End Results (SEER) data (179,184) suggest a modest improvement in survival, with 10-year relative survival of 64.8% in women and 50.5% in men. While localized disease carries 5-year survival rates in the 67% to 81% range, patients with regional lymph node metastases show survival rates of approximately 50%, and patients with distant metastases show rates in the 10% to 20% range. (179,184)
Histologically, MCC is predominantly based in the dermis, with some tumors showing a subcutaneous and intraepidermal component (Figure 6, A). Cytologically, it is a "small round blue cell tumor" whose cells have a high nuclear to cytoplasmic ratio, large basophilic nuclei with fine chromatin, and high mitotic activity (Figure 6, B). The cells predominantly grow in sheets or nodules, with some tumors showing a trabecular pattern. Often lymphovascular invasion is seen, consistent with MCC's high propensity to cause early lymph node metastases (Figure 6, C). Tumor thickness may correlate with outcome. (185)
The tumor cells show ultrastructural features of Merkel cells. (186,187) Merkel cells are believed to be of neuroendocrine origin and act as epidermal mechanoreceptors. (188) However, it is currently not clear if MCC is derived from epidermal Merkel cells or, alternatively, is a tumor with neuroendocrine differentiation that is derived from a common epidermal stem cell precursor. (189) Positivity for cytokeratin 20, which also is present in normal Merkel cells, is the most important diagnostic immunohistochemical marker for MCC. (190) Cytokeratin immunoreactivity is found in a "perinuclear dotlike" pattern, as seen in many neuroendocrine neoplasms (Figure 6, D). Merkel cell carcinoma often stains positively for neurofilament protein and the neuroendocrine markers chromogranin and synaptophysin. (191) In some cases it is important to perform immunostaining with thyroid transcription factor 1 to rule out a metastatic visceral small cell carcinoma, which is often positive in this entity and negative in MCC (as is cytokeratin 7 in most, but not all, cases). S100 immunostaining can be performed to rule out melanoma and, if necessary, CD99, to rule out Ewing sarcoma/peripheral neuroectodermal tumor in which it shows strong membranous reactivity. p63 expression portends a poor prognosis. (192)
The development of MCC is associated with UV irradiation, immunosuppression, and Merkel cell polyomavirus integration, with a significantly elevated risk in patients with organ transplants, patients with chronic lymphocytic leukemia, and patients with HIV infection. (193-197) UV-associated mutations in the TP53 tumor suppressor gene are commonly seen. (198) Multiple chromosomal abnormalities such as trisomy 6, LOH at chromosome 13, and deletions and insertions of chromosome band 1p36 have been reported. (199-202) 1p36 deletion is seen in other neuroendocrine tumors and melanoma, suggesting a neural crest origin of MCC. More recently, array comparative genomic hybridization has shown a complex pattern of gains and losses, with deletions at 5q12-21 and 13q14-21 and a focal amplification at 1p34 present in 39% of MCC, that contain the MYCL1 proto-oncogene, which encodes LMyc. (203) Less genomic aberrations correlated with improved survival in this study. While mutations in the CDKN2A gene encoding the [p16.sup.INK4a] and [p14.sup.ARF] tumor suppressors are rare in MCC, promoter hypermethylation, and thus silencing of [p14.sup.ARF] expression (and less commonly [p16.sup.INK4a]), may play a role in MCC. (204)
Merkel cell carcinoma tumor cells express the c-Kit/ CD117 transmembrane receptor tyrosine kinase. (205) However, only silent or intronic, but no activating, KIT gene mutations were found in subsequent studies. (206-208) Along with those observations, an initial trial with imatinib (which targets c-Kit) proved that this drug is ineffective in MCC. (209) High c-Kit expression was recently proposed to represent an adverse prognostic factor. (206)
Alterations in the Wnt/[beta]-catenin and Ras-Raf-Erk pathways likely play no major role in MCC. (210-212) While LOH of the PTEN (phosphatase and tensin homologue) tumor suppressor gene was found in a fraction of MCCs, mutations appear to be uncommon. (213) Recent studies (214) showed that the phosphoinositide-3 kinase (PI3K)/Akt pathway, which is negatively regulated by PTEN, is activated in most MCCs. However, PI3KCA mutations were found only in a small fraction of tumors. (214,215)
Polyomaviruses, such as the SV40, BK, or JC viruses, are small double-stranded DNA viruses that have long been known to cause cancers in animal models, but their role in human carcinogenesis is not proven. Recently, clonal integration of a novel 5387-bp polyomavirus termed Merkel cell polyomavirus (MCV) was demonstrated in MCC. (194) It is still not entirely clear if it plays a causal role in tumor development. While a fusion gene of the viral large T region sequence with the human receptor tyrosine phosphatase gene PTPRG, which is supposed to act as a tumor suppressor, has lead to detection of MCV, viral DNA is randomly inserted in the genome, arguing against a causal role of this specific fusion gene. Thus, it is unclear if a role in tumor development may be due to insertional mutagenesis or due to expression of its oncoprotein, the viral large T antigen, or both. Viral T antigens transform cells by binding to tumor suppressor gene products such as p53 and Rb, and cell cycle regulatory proteins, and are involved in viral replication through their helicase/adenosine triphosphatase activity. Interestingly, inactivating mutations of the large T sequences, rendering the virus replication inactive owing to premature truncation of the transcript (but leaving a potentially transforming Rb-interacting domain intact), were found selectively in clonally integrated viruses, arguing against a secondary infection of preexisting tumors. (216)
Subsequent studies found that MCV is present in up to 88% of MCCs from European and North American patients. (217-219) However, a small fraction of other skin tumors, such as SCC, BCC, Kaposi sarcoma, or cutaneous lymphomas, are also positive for MCV. (220-223) Initial studies (224) suggest that virus-positive MCC occurs more often on the extremities, less frequently presents with nodal metastases, and is associated with a better survival rate. Virus-positive tumors were also found to show fewer genomic deletions, along with better survival, in another small series. (203) However, currently there is no consensus as to whether virus-positive tumors carry an overall better prognosis. (192,225-228)
The following selected adnexal neoplasms often occur in the head and neck region and show interesting molecular genetic findings as well as associated hereditary conditions (summarized in Table 1). Typically, they have rare malignant counterparts, which sometimes cannot be easily separated from the benign entities, and therefore are included in the discussion of the benign conditions.
Background.--Trichilemmoma.--Trichilemmoma is a tumor with hair follicle differentiation that can be solitary or multiple (the latter can be associated with Cowden disease and is discussed under "Hereditary Conditions" below). Solitary trichilemmoma typically presents as a single, small, skin-colored papule, either with a smooth or verrucous surface, most commonly seen on the face of older individuals. (229,230) The most common sites are the nose and eyelid, and it can also be found associated with a nevus sebaceous. (231,232) Histologically, it resembles the outer root sheath of the hair follicle with lobules of small uniform cells with regular round to oval small nuclei that appear to arise from the epidermis or hair follicles (Figure 7, A). The cytoplasm often appears clear owing to glycogen accumulation (Figure 7, B). In the periphery of the lobule, the cells show nuclear palisading and are bordered by a hyalinized rim. Hyperkeratosis and parakeratosis of the epidermal surface is typically seen. Sometimes, there can be pronounced keratinization and squamous eddy formation, resembling an irritated seborrheic keratosis, or marked verrucous changes, mimicking verruca vulgaris. Desmoplastic trichilemmoma is a variant that is not associated with Cowden disease. It shows irregular extensions of epithelial nests within a central sclerotic stroma, which can sometimes lead to problems distinguishing it from an invasive carcinoma.
Trichilemmal Carcinoma.--Trichilemmal carcinoma is rare and is also found on sun-exposed skin, especially head and neck sites. (233-235) Despite being locally aggressive, it generally shows a relatively benign course. Invasive trichilemmal carcinoma typically shows a pushing border. As opposed to trichilemmoma, the clear cells show varying degrees of pleomorphism (variation in cell size and shape), nuclear atypia, and elevated mitotic rate. Trichilemmal keratinization (ie, without a granular cell layer) is usually seen, and often there is peripheral palisading.
Hereditary Conditions.--Cowden disease (multiple hamartoma syndrome) is an autosomal dominant condition with a female predominance, which is characterized by multiple hamartomas in several organ systems. (236,237) It is characterized by a markedly elevated risk for the development of breast adenocarcinoma (men can also be affected), but patients can also develop thyroid carcinomas (most often follicular carcinomas) and other malignancies. (236,238,239) According to most recent data, estimated lifetime risks are 85.2% for breast carcinoma, 35.2% for thyroid carcinoma, 28.2% for endometrial carcinoma, 9.0% for colorectal carcinoma, 33.6% for kidney carcinoma, and 6% for melanoma. (240) Mucocutaneous manifestations are multiple facial trichilemmomas, especially surrounding the nose, mouth, and ears, as well as sclerotic fibromas, acrochordons, punctate keratoses of the palms and soles, acrokeratosis verruciformis, and oral papillomas ("scrotal tongue"). (241-243) Other associations are macrocephaly, Lhermitte-Duclos disease (a hamartomatous overgrowth of cerebellar tissue), thyroid follicular adenomas and goiter, fibrocystic breast disease, ovarian cysts, and colonic polyps. (238)
Histologically, some of the facial hamartomas may show typical features of trichilemmoma, while others may resemble an irritated seborrheic keratosis or a tumor of follicular infundibulum. (237,238,241-245) The dermal fibromas resemble storiform collagenoma with its characteristic whorled growth pattern. (243)
Molecular Pathology.--The PTEN gene on 10q23 shows germline mutations in approximately 80% of patients with Cowden disease. (246-249) PTEN is a tumor suppressor gene involved in apoptosis and cell cycle arrest. (250,251) It is a dual-specificity lipid and protein phosphatase that uses the PI3K product, phosphatidylinositol-3,4,5-triphosphate (PIP3), as a substrate and thus negatively regulates the PI3K/Akt pathway. PIP3 is required for the activation of Akt at the plasma membrane, which is a serine/threonine kinase involved in regulation of cell survival. Independently, PTEN can negatively affect the mitogen-activated protein (MAP) kinase pathway (via the Shc and Gab1 adapters) and focal adhesion kinase through its protein phosphatase activity. More than 150 frameshift, nonsense, and missense mutations have been described, and there appears to be a correlation between the presence of a PTEN mutation and breast carcinoma. (250,252,253) Seventy-six percent of the mutations lead to protein truncation, lack of protein, or a dysfunctional protein. A subset of the 20% of patients with no documented PTEN mutations likely possess loss-of-function mutations of the PTEN promoter sequence or may show inactivation of PTEN through NEDD4 (neural precursor cell expressed developmentally down-regulated protein 4) ubiquitin protein-mediated degradation, or PTEN promoter hypermethylation. (246,254) Differential expression of microRNA's miR-19a and miR-21 may also affect PTEN expression levels in patients with Cowden disease. (255) Approximately 40% of the PTEN mutations occur in the exons coding for the core phosphatase domain and the C-terminal C2 domain, which is responsible for phospholipid binding. (250) In addition, PTEN has recently been shown to exert its tumor suppressor function via ubiquitination and subsequent nuclear import, where it may help to maintain chromosome stability, and mutations have been found in ubiquitination sites in patients with Cowden disease. (256,257) Recently, PI3KCA mutations were described in a subset of patients with Cowden syndrome without PTEN mutations. (258)
In a small study using immunohistochemistry, PTEN loss was observed in most Cowden syndrome-related trichilemmomas, while most sporadic trichilemmomas showed retained expression. (259)
PTEN mutations have also been found in Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Proteus-like syndrome, and it has been proposed that these disorders be classified together as "PTEN hamartoma syndromes." (252,253,260) However, an increased risk of malignancy has been demonstrated only for Cowden disease so far. (246,252)
KILLIN is a tumor suppressor gene and p53 target, which inhibits DNA synthesis through S phase arrest. (261) Interestingly, it is encoded by the PTEN locus and transcribed in the opposite direction; promoter hypermethylation in a fraction of patients with Cowden disease leads to decreased KILLIN gene expression and p53-mediated activation of killin. (262)
Background.--Cylindroma is a benign tumor of sweat gland derivation and mainly affects females. (263,264) It occurs predominantly in the head and neck region with the scalp being the most common site. Solitary or multiple tumors are typically red or pink small nodules.
Histologically, cylindroma is based in the dermis and consists of multiple tumor lobules of different shapes and sizes, surrounded by a prominent periodic acid-Schiff-positive basement membrane, and arranged in a jigsaw puzzle pattern without epidermal connection (Figure 8). Usually, the cells in the periphery are smaller with a relatively high nuclear to cytoplasmic ratio and dark hyperchromatic nuclei with palisading. They surround larger cells with a paler cytoplasm and vesicular nuclei. Nodular deposits of hyaline material and ductal lumina may also be seen within lobules. Immunopositivity of ductal elements for carcinoembryonic antigen, as well as cytokeratin 7 and epithelial membrane antigen positivity, may aid in diagnosis and is suggestive of eccrine gland derivation, but apocrine derivation has also been proposed. (264-266) Malignant cylindroma very rarely arises in a preexisting benign cylindroma and shows significant potential for recurrence and metastasis. (267,268)
Hereditary Conditions.--Multiple cylindromas (socalled turban tumor) are seen in familial cylindromatosis (Brooke-Spiegler syndrome), which is inherited in an autosomal dominant fashion. (269-272) Typically, tumors start to develop in the second and third decade of life. Patients may also develop facial trichoepitheliomas, eccrine spiradenomas, and milia, with highly variable expressivity. (273-275) Patients may also develop membranous basal cell adenomas ("dermal analogue tumor") of the major salivary glands, which have a similar histologic appearance. (276-278) The development of malignant cylindromas and basal cell adenocarcinomas has been described in patients with cylindromatosis and is more common in tumors from individuals with the inherited condition than in tumors from unaffected individuals. (267,278-281)
Molecular Pathology.--The gene associated with familial cylindromatosis, CYLD1 (cylindromatosis 1), is located on 16q12-13, and is a tumor suppressor gene. (282) Tumors from patients with the syndrome show mutations in CYLD1 , usually associated with LOH or with somatic mutations of the second allele, and LOH and somatic mutations are also seen in sporadic tumors. (283-286) Loss of heterozygosity at 16q12-13 was also described in membranous basal cell adenomas of the parotid gland, (287) and CYLD mutations were found in multiple familial trichoepitheliomas, suggesting that it represents a related condition. (288,289) The mutations are located in the 3' two-thirds of the coding sequence, predominantly resulting in truncation of the protein product, due to a frameshift secondary to small insertions or deletions, creation of stop codons secondary to point mutations, or due to alteration of splice sites. (284,290-292) Somatic mutations were found both in sporadic and familial tumors and result in truncation or deletion of the encoded protein. (284) While a correlation between specific mutations and certain phenotypes has been proposed, (290) such genotype-phenotype correlations have been contested by others. (293)
CYLD1 is a 956-amino acid protein that is widely expressed. (284) It is involved in regulation of the NF-[kappa]B pathway, which is a transcription factor involved in regulation of inflammatory responses and apoptosis upon multiple cellular stimuli, including tumor necrosis factor (TNF) receptor family members. NF-[kappa]B is activated by inhibitor of [kappa]B (I[kappa]B) kinases, followed by degradation of the inhibitory I[kappa]B molecule, which then leads to release and nuclear translocation of NF-[kappa]B. (294,295) It appears that CYLD interacts with NF-[kappa]B essential modulator and TNF receptor-associated factor 2, a regulator of I[kappa]B kinase, and is capable of deubiquitinylation through its C-terminal hydrolase domain, leading to subsequent NF-[kappa]B inhibition. (296,297) In the absence of CYLD expression, NF-[kappa]B activation and decreased apoptosis are observed. (298) This inhibitory activity also results in delayed mitotic entry. (299) CYLD appears to have a negative effect on Jun kinase signaling as well. (300) More recent data point toward a broader negative regulatory effect of CYLD. For example, CYLD suppresses the Wnt/[beta]-catenin pathway through its deubiquitinylating activity. Consequently, cylindromas show hyperactive Wnt signaling. (301) In addition, the N-terminal cytoskeleton-associated protein-glycine-conserved domain of CYLD appears to be involved, together with microtubules and tubulin, in Bcl-3-mediated G1/S phase cell cycle delay and inhibition of cytokinesis in the late stages of mitosis. (302) However, no mutations in the regions coding for this domain have been found in patients with familial cylindromatosis.
Background.--Sebaceous adenoma typically presents in older individuals with a female predominance. It is usually a small yellow or slightly pink nodule that is predominantly found in the head and neck region, often the face or scalp. (303,304) Histologically, sebaceous adenoma is a tumor that maintains a lobular architecture with an epidermal connection. Centrally, within the lobules are mature sebaceous cells with foamy pale cytoplasm and central indented nuclei. While these represent more than 50% of the lesion, in the periphery of the lobule basaloid immature cells ("seboblasts") with only small amounts of cytoplasm are found (Figure 9, A).
Sebaceoma is found within a similar demographic group and also most commonly presents in the head and neck region, but is typically larger than sebaceous adenoma. (304-306) Histologically, it consists of multiple dermal nodules or lobules, which often show an epidermal connection and a greater amount of basaloid cells (>50%) than in sebaceous adenoma. Typically, basaloid cells and sebaceous cells are also intermixed and lack the distinct maturation seen in sebaceous adenoma (Figure 9, B). Often, ducts can be appreciated. As opposed to sebaceous carcinoma, significant nuclear pleomorphism and stromal invasion are absent.
Sebaceous carcinoma most commonly presents in a periocular location, with the remainder of cases predominantly found in sebaceous gland-rich regions of the head and neck. (303,307) Periocular sebaceous carcinoma is estimated to represent 1.1% to 5.5% of all eyelid malignancies. It typically arises from the meibomian (tarsal) glands and is more frequently seen in the upper lid. Clinically, it presents as an indistinct slow-growing nodule that is often misdiagnosed as a chalazion or other type of tumor such as BCC. Local recurrence has been reported in 9% to 36% of cases and metastasis in 14% to 25%. (307) Extraocular tumors are erythematous or yellow nodules or plaques that can reach a significant size. Prognosis is comparable to that of periocular lesions. (307,308) Histologically, sebaceous carcinoma often shows invasion into the subcutis and skeletal muscle of the eyelid, and contains a mixture of basaloid cells and more mature-appearing sebaceous cells. Depending on the degree of differentiation, significant pleomorphism, nuclear atypia, necrosis, and atypical mitoses can be present, with only rare mature cells in some cases (Figure 9, C). Periocular lesions typically show intraepidermal pagetoid spread of tumor cells, which is less commonly seen in extraocular tumors.
Hereditary Conditions.--Muir-Torre syndrome is a phenotypic variant of the human nonpolyposis colorectal carcinoma (HNPCC or Lynch) syndrome with mainly autosomal dominant inheritance, found in fewer than 10% of patients with this condition. (309-313) Patients with HNPCC develop internal malignancies, most commonly colorectal carcinomas with a lifetime risk of 80%, but also genitourinary and other visceral malignancies, at an earlier age than patients with sporadic tumors. Colorectal carcinomas are more commonly right sided in these patients, sometimes multiple, and generally carry a better prognosis. (314,315)
The most specific cutaneous finding in patients with Muir-Torre syndrome is sebaceous adenoma, but other sebaceous neoplasms, such as sebaceoma, sebaceous carcinoma, and occasionally also keratoacanthomas, are also seen. (316,317) The cutaneous neoplasms often precede associated internal malignancies, making early diagnosis critical. Sebaceous carcinomas also show an early onset in patients with the syndrome, when compared to patients with sporadic tumors. (318) While sebaceous neoplasms associated with Muir-Torre syndrome show certain suggestive histopathologic features such as "keratoacanthoma-like" changes, potentially a cystic architecture (although there is no agreement between studies here), and are more likely to be found on the trunk and extremities as opposed to a head and neck location, (319-323) molecular analysis is considered the gold standard (see below).
Molecular Pathology.--HNPCC and Muir-Torre syndrome show defects in mismatch-repair genes. (314) Mismatch repair is a process in which errors made by DNA polymerase, which accumulate during DNA replication in the elongation phase, are removed. The most common error is mispairing of nucleotides, but "slippage" of the DNA polymerase complex can also create errors in short repetitive DNA sequences termed microsatellites, which typically are mononucleotide or dinucleotide repeats. (314) Mismatch repair mechanisms correct these errors, but in the setting of deficient mismatch repair, these errors accumulate and create microsatellite instability (MSI). The mismatch repair system consists of human mutS homolog 2 (hMSH2), human mutS homolog 3 (hMSH3), human mutS homolog 6 (hMSH6), human mutL homolog 1 (hMLH1), and human postmeiotic segregation increased 2 (hPMS2) proteins, among others. Initially, a complex of hMSH2 and hMSH3 (or hMSH6) binds directly to the DNA segment containing the error, which then leads to recruitment of a complex of hMLH1 and hPMS2, leading to excision of the DNA sequence. (324,325) Mutations in MLH1 and MSH2 have the most severe effect, producing an "MSI-high phenotype," and are also most commonly observed in patients with HNPCC. (326,327) Accumulation of MSI in growth regulatory and tumor suppressor genes, such as the Bloom syndrome helicase gene, the proapoptotic BAX gene, PTEN, and the E2F4 transcription factor involved in cell cycle control, is then thought to drive tumorigenesis. (328)
Microsatellite instability is also seen in most patients with Muir-Torre syndrome, with the MSH2 locus more commonly affected than the MLH1 locus. (329,330) More recently, cases with loss of hMSH6 have been reported, which appears to be linked to hMSH2 loss. (323,331) Loss of hMSH2 or hMLH1 expression in sebaceous neoplasms, as demonstrated by immunohistochemistry, is suggestive of Muir-Torre syndrome. (323,331-333) The diagnosis can then be confirmed by genomic polymerase chain reaction analysis, in which certain highly unstable MSI markers are assessed for their instability by electrophoretic assessment of size distribution of amplified fragments (Figure 10, A and B). (334-337) In recent studies, (321,323) sebaceous neoplasms associated with mismatch repair deficiency were found to be more common on the extremities and trunk than head and neck, were more often benign, and showed keratoacanthoma-like features, while cystic changes were not found to be associated.
Sporadic sebaceous neoplasms do not show MSI and loss of mismatch repair gene expression. (332,333) In sporadic sebaceous carcinomas, TP53 mutations have been reported (without a UV signature at least in periocular carcinoma), and p53 accumulation is seen by immunohistochemistry in carcinoma, but not in benign sebaceous neoplasms. (338-341) In addition, the cell cycle regulator p21WAF1 is lost in some compartments in sebaceous carcinoma, but not in benign sebaceous neoplasms. (342) In Asian patients, HPV appears to play a role in tumorigenesis. (339,340)
More recent studies (343-345) have also proposed a role for the Wnt/[beta]-catenin pathway and the downstream target lymphoid enhancer binding factor 1 (Lef-1), a transcription factor, in the pathogenesis of sebaceous neoplasms (for details see next section on "Pilomatricoma"). Interestingly, LEF1 mutations were found in benign sebaceous neoplasms, irrespective of MSI status, and were shown to lead to inhibition of [beta]-catenin association and suppression of Wnt/[beta]-catenin target genes, while markers of sebaceous differentiation were upregulated in those tumors, which may explain their differentiated characteristics. (345) Mutations in the fragile histidine triad tumor suppressor gene, a repressor of [beta]-catenin transcriptional activity, have recently been found in sebaceous carcinomas irrespective of MSI status. (346,347)
Pilomatricoma and Pilomatrix Carcinoma
Background.--Pilomatricoma (pilomatrixoma) is a benign tumor of hair matrix differentiation that mainly occurs in young patients, predominantly children, although older patients, especially during late middle age, can be affected as well. (348-351) The most commonly affected site is the head and neck region, especially the cheek and neck. (156,349,351) Typically, it presents as a firm nodule or cyst that is usually less than 3 cm. A low possibility of recurrence was observed after surgical excision in some studies, but not others. (349,351,352) Pilomatricoma can be associated with Gardner syndrome, myotonic dystrophy, or rarely, Turner syndrome and Rubinstein-Taybi syndrome. (348,353-356) Pilomatrix carcinoma is a very rare tumor that usually occurs in the head and neck region in adults. It typically is larger than pilomatricoma and presents more frequently in older males, as opposed to pilomatricoma which shows a female predominance. (350,357,358) Occasionally, a preexisting benign pilomatricoma is found. (359) Metastases are relatively uncommon, but there is a significant potential for recurrence. (350,357,358)
Histologically, pilomatricoma is a well-circumscribed, dermal-based tumor, consisting of multiple lobules, and shows hair matrix differentiation. It consists of peripheral small basaloid cells with a high nuclear to cytoplasmic ratio and round nuclei, and central "ghost" or "shadow" cells with a pink cytoplasm and small pyknotic nuclei, which are lost upon further maturation (Figure 11). The basaloid cells can show striking mitotic activity, especially in early lesions, which on its own is not a feature of malignancy. Calcifications are typically seen in older lesions. Pilomatricoma, especially in adults, may occasionally show additional atypical features, such as atypical mitoses, pleomorphism, and nuclear atypia, which appear to have no clinical significance. (350,360) The presence of additional atypical features, such as large areas of tumor necrosis, infiltrative growth, lymphovascular or perineural invasion, or large tumor size, however, should raise the possibility of pilomatrix carcinoma. (357,361)
Molecular Pathology.--Pilomatricomas exhibit mutations of CTNNB1, which is the gene encoding [beta]-catenin. (362-364) [beta]-Catenin is a 92-kDa molecule involved in cellcell adhesion in adherens junctions, where it links cadherins to the actin cytoskeleton. (365) It is also an essential component of the Wnt signaling pathway. (366,367) The Wnt pathway is a ligand-activated, highly conserved pathway that regulates cell fate during embryogenesis. One of the best-characterized Wnt pathways is the canonical Wnt pathway, which specifically involves [beta]-catenin and regulates cell proliferation, differentiation, and survival. (366,367) It has been found to play a critical role in many malignancies as well as inherited diseases. (366,368) For example, activated Wnt signaling and CTNNB1 mutations have been found in colorectal carcinomas, melanomas, endometrial adenocarcinomas, and hepatocellular carcinomas. (366,367)
In the absence of Wnt, free cytoplasmic [beta]-catenin is rapidly phosphorylated at its N-terminus by the kinases GSK3[beta] (glycogen synthase kinase-3[beta]) and CK1[alpha] (casein kinase-1[alpha]), leading to its ubiquitinylation and proteasomal degradation by a "destruction complex," which is coordinated by the scaffolding protein Axin and also contains the adenomatous polyposis coli tumor suppressor gene product. (366,367,369) In activated Wnt signaling, binding of extracellular secreted Wnt glycoproteins to the Frizzled/LRP (lowdensity-lipoprotein receptor-related protein) receptor complex leads to suppression of [beta]-catenin phosphorylation. This is likely achieved by the recruitment of the scaffolding proteins Axin and Dishevelled (Dsh) to the Wnt receptor complex instead of the kinase-containing destruction complex, and consequently leads to its stabilization through decreased phosphorylation and degradation. (366,368) Accumulating [beta]-catenin then enters the nucleus in a process that involves Rac guanosine triphosphatase (GTPase) and forms a complex with the Lef/Tcf (Lef/T-cell factor) transcription factor, which displaces the Lef-associated corepressors TLE/ Groucho and histone deacetylase and converts Lef from a transcriptional repressor to a transcriptional activator. (366-368,370,371) Lef then activates proto-oncogenes such as
CMYC and CCND1 (cyclin D1). (372,373) This proposed pathogenetic mechanism is illustrated in Figure 12.
Mutations in CTNNB1 are located in the exon 3 region of the gene, which encodes the N-terminal phosphorylation sites. At these sites, missense mutations cause alterations of the serine and threonine phosphorylation sites that are substrates for GSK3, thus leading to [beta]-catenin stabilization through decreased phosphorylation and degradation. (362) Accordingly, strong nuclear and cytoplasmic [beta]-catenin positivity and strong nuclear Lef-1 positivity are seen in basaloid cells in pilomatricoma by immunostaining. (362-364) The [beta]-catenin target cyclin D1 can also be detected by immunohistochemistry in pilomatricoma. (374) Similar mutations and nuclear [beta]-catenin-staining patterns can also be found in pilomatrix carcinomas. (357) The fundamental role of [beta]-catenin in hair follicle morphogenesis and development of pilomatricomas was also shown in mice expressing a stabilized truncated [beta]-catenin transgene. (375)
[beta]-Catenin expression is also found in the emerging hair matrix during human embryogenesis, supporting its role in hair follicle development and also a hair matrix origin for pilomatricoma. (368,376)
Recently, trisomy 18 was found in the basaloid component of pilomatricoma, and it was speculated that genes such as Bcl2, which is located on chromosome 18, may play a role in tumorigenesis. (377)
Melanoma comprises an estimated 5% of cancers in men and 4% in women according to 2010 US cancer statistics (which exclude the much more common nonmelanoma skin cancers (3)). The incidence of melanoma has been increasing with annual rates of 3% to 7% during the last decades. (378) Melanoma mainly affects middle-aged adults with a current median age of 61 years in the United States. (379) The age-adjusted incidence rate in the United States was 21.1 per 100 000 between 2006 and 2010. (379) The main environmental risk factor for the development of the more common forms of melanoma appears to be UV exposure, and thus it mainly affects fair-skinned individuals. (380-383) It is also commonly seen in patients with XP. Patients with multiple common nevi and multiple dysplastic nevi are also at increased risk. (383-385) Melanoma shows a slight male predominance, especially in the head and neck region, although overall the most common sites are the back in men and the legs in women. Most commonly, melanoma arises de novo, although a significant proportion (approximately 25%) arise in association with preexisting benign, congenital, or dysplastic nevi. (386,387) Worrisome clinical signs for melanoma are asymmetry, irregular border, dark or variegated pigmentation, a diameter greater than 6 mm, and recent change. (388,389)
The prototypic subtypes of melanoma are superficial spreading, nodular, acral lentiginous, and lentigo maligna melanoma, with lentigo maligna melanoma being relatively more common in the head and neck region. (390,391) Superficial spreading melanoma typically arises on the back or legs, presents as an irregularly pigmented macule or plaque, and is the most common variant. Nodular melanoma also prefers those anatomic sites and presents as an often ulcerated black or blue nodule.
Lentigo maligna melanoma represents approximately 10% of melanomas and typically presents as a slowly enlarging, asymmetric, brown to black macule with irregular pigmentation on sun-exposed skin. (390) It affects an older age group and is related to chronic sun exposure, while the more common types of cutaneous melanoma, such as superficial spreading melanoma, are related to acute intermittent exposure. (391-394) Desmoplastic melanoma is an uncommon form of melanoma, accounting for approximately 1% of all cases, which also affects an older age group with a median age of 66 years, from recent SEER data. (395-397) It occurs in chronically sun-damaged skin, and with 51% of all cases it predominantly affects the head and neck region. (397) While sometimes associated with lentigo maligna, it is often amelanotic and deeply infiltrative.
Recently, epidemiologic analysis led to the proposal of an "early-onset melanoma" category, which is predominantly associated with female sex, superficial spreading melanoma, and a lower extremity location, and a "late-onset melanoma" category, which is predominantly associated with male sex, lentigo maligna melanoma, and a head and neck location. (398) In this model, early and/or intermittent sun exposure may be responsible for early-onset melanomas in more susceptible individuals, and accumulated life-long sun exposure may be responsible for late-onset melanomas in less sensitive individuals.
The overall 5-year relative survival was 91.7% between 2001 and 2007 in the United States. (379) In general, adverse clinical prognostic factors are male sex, older age, ulceration, and location in the head and neck region, especially the scalp, as well as back and upper arms. (399-402) An analysis of SEER data (403) found that patients with melanoma in the head and neck region, when adjusted for other prognostic parameters, were 1.84 times more likely to die from the disease when compared to melanomas arising in other sites. However, the prognosis of lentigo maligna melanoma overall appears to be equal, or slightly better, than that of other melanoma subtypes. (404,405) Desmoplastic melanoma shows increased local recurrence rates, compared to other melanoma subtypes. By contrast, lymph node metastases are less common than in other melanoma subtypes, with fewer than 10% positive sentinel lymph node biopsy results in larger series. (396,397,406,407) Survival is better than for other melanoma types, when adjusted for other prognostic parameters such as thickness. (408-411)
Histologic Features and Immunohistochemistry
Melanoma is a malignant melanocytic neoplasm that can either exist as melanoma in situ with malignant cells being limited to the epidermis, radial growth phase melanoma with limited invasion into the superficial dermis, or vertical growth phase melanoma with tumorigenic invasive growth extending into deeper tissues or the presence of mitotic activity in the invasive component. (412) These are believed to represent sequential steps in tumor progression.
Histopathologic prognostic markers are used for various staging systems such as the TNM system (tumor characteristics, presence and characteristics of nodal metastases, and presence and sites of distant metastases), which forms the basis of the American Joint Committee on Cancer melanoma staging and classification. (413) Briefly, the most important histopathologic criteria for the primary tumor are Breslow tumor thickness, mitotic rate, and ulceration. (413) Other factors are the presence of tumor infiltrating lymphocytes, lymphovascular invasion, microsatellites, and Clark anatomic level of invasion. Tumor thickness (414) remains the most important histologic prognostic factor and is measured from the top of the granular cell layer to the deepest portion of the tumor. From the current classification, patients with T1aN0M0 melanomas (ie, melanomas with <1 mm thickness, no ulceration, and no dermal mitoses) have a 5-year survival rate of 97% and patients with locally advanced T4bN0M0 melanomas (ie, ulcerated melanomas >4 mm thickness) have a 5-year survival rate of 53%. (413) The prognosis for melanoma with distant metastases is very poor.
The histologic profile of superficial spreading melanoma consists of an asymmetric proliferation of uniformly atypical melanocytes that are found at all levels of the epidermis, with single or small aggregates of atypical melanocytes present in the stratum corneum or granulosum ("pagetoid growth"). Typically, the tumor cells both of the in situ and the invasive component are epithelioid with large amounts of cytoplasm, have atypical large vesicular nuclei with prominent nucleoli, and often contain melanin pigment. Nodular melanoma shows an absent or a less-pronounced intraepidermal component, which by definition is limited to maximally 3 epidermal rete ridges lateral to the invasive component.
Lentigo maligna in its pure form does not show pronounced pagetoid spread and consists of a contiguous proliferation of atypical melanocytes located at the lower levels of the epidermis. In contrast to the epithelioid cells with vesicular nuclei that are seen in superficial spreading melanoma, the cells show large angulated hyperchromatic nuclei and often a cytoplasmic retraction artifact (Figure 13, A). Adnexal involvement by atypical melanocytes is typically seen. Histologic signs of chronic sun damage, such as epidermal atrophy with loss of rete ridges and solar elastosis, are often present. While some authors consider that both prototypic lentigo maligna and more advanced lesions with confluent growth, pagetoid spread, and nest formation represent melanoma situ, others distinguish lentigo maligna from lentigo maligna melanoma in situ. (415) The invasive component of lentigo maligna melanoma sometimes shows spindle cells and collagen deposition that can lead to a desmoplastic appearance.
Desmoplastic melanoma is often amelanotic and often consists of a proliferation of only mildly atypical spindle cells in a fibrotic collagenous stroma, which typically invade deeply, reminiscent of a scar or a nonmelanocytic spindle cell neoplasm (Figure 13, B), thus occasionally leading to a wrong diagnosis. Sometimes a grenz zone, devoid of tumor cells, is seen in the papillary dermis. Nodular aggregates of lymphocytes are often seen, particularly at the margins of the tumor. Perineural invasion is a characteristic feature and may be associated with recurrence. Neurotropism, which is defined by some as extensive endoneural and perineural invasion, and as Schwann cell-like differentiation of tumor cells by others, can also be seen. An intraepidermal component may be lacking or, if present, may show features of lentigo maligna. Classical histologic prognostic parameters may not be good predictors of outcome in desmoplastic melanoma, but pure desmoplastic melanomas may have a better prognosis than tumors with a nondesmoplastic component. (407,409)
Melanoma is almost always positive for the immunohistochemical marker S100. However, S100 antibodies also label a broad range of other normal cells, such as Langerhans cells and other types of histiocytes, chondrocytes, or adipocytes, as well as other neoplasms such as schwannomas, neurofibromas, malignant peripheral nerve sheath tumors, and clear cell sarcomas ("melanoma of soft parts"). Carcinomas can occasionally stain with S100 as well. More specific markers that help to differentiate these--apart from clear cell sarcoma, which in difficult cases may require molecular genetic tools--are the melanoma antigens MART-1/Melan-A, the melanosomal glycoprotein HMB-45 (gp100), and microphthalmia transcription factor (MiTF). However, these markers often show negativity in invasive spindle cell and desmoplastic melanomas. Microphthalmia transcription factor also stains fibroblasts, smooth muscle, Schwann cells, and various inflammatory cells, limiting the use of these markers for these types of melanomas. In addition, they usually also stain positively in benign melanocytic lesions. Thus, an accurate differential diagnosis often relies on morphologic features, such as the identification of an in situ component, if present, and the exclusion of other entities through a panel of additional immunohistochemical markers, for example, keratins and p63 for the exclusion of spindle cell squamous cell carcinomas (although melanomas sometimes show keratin reactivity).
In approximately 10% of cases, melanoma is familial. Twenty percent to 30% of affected patients have mutations in the CDKN2A tumor suppressor gene at 9p21, which encodes [p16.sup.INK4a] and [p14.sup.ARF]. (416-419) As mentioned above, p16 inhibits CDK4, which, together with cyclins, regulates G1-S transition via RB phosphorylation and activation of the EF2 transcription factor. (420) CDKN2A missense mutations associated with familial melanoma render p16 catalytically inactive. (421) Mutations occur in exon 1a (affecting [p16.sup.INK4a] only), in exon 2 (affecting either [p16.sup.INK4a] or [p14.sup.ARF] or both), or in the 50 untranslated region (affecting [p16.sup.INK4a]) and most often are nucleotide exchanges. (422) Mutations that affect both [p16.sup.INK4a] and [p14.sup.ARF] result in the highest risk for development of melanoma, followed by missense mutations affecting [p16.sup.INK4a] only. (423) Typically, melanoma develops at a younger age in these patients, melanomas are sometimes multiple, atypical nevi are often present, and there is an increased risk for pancreatic carcinoma. (416,418) A very small fraction of patients with familial melanoma show mutations in the CDK4 gene itself, rendering CDK4 unable to bind to its inhibitor [p16.sup.INK4a]. (416,418) As mentioned above (see earlier section on "Basal Cell Carcinoma"), melanocortin receptor mutations affect skin pigmentation in white persons, and certain "red hair" variants carry a mildly elevated risk for the development of melanoma. (424)
Ras/Raf/MAPK (mitogen-activated protein [MAP] kinase) Pathway.--The above described CDKN2A germline mutations occur infrequently in patients with sporadic first melanoma (12% as based on a recent study (423)). However, many melanomas show mutations in genes encoding for proteins that are part of the Ras/Raf/MAPK signaling pathway. (425) Overall, up to 80% of all melanomas show either BRAF or NRAS mutations. (426-434) These mutations lead to increased activity of the MAPK pathway. More than half of all melanomas show mutations in the BRAF protooncogene, predominantly a T to A nucleotide transversion leading to a V599E amino acid substitution within the activation segment of the Raf serine/threonine kinase gene product, increasing its catalytic activity and subsequently activating MEK (MAP kinase kinase) and ERK MAP kinases. (427,431,435)
Interestingly, a similar or even higher BRAF mutation frequency has been found in normal nevi, suggesting that additional molecular alterations are necessary for the development of melanoma. (435,436) While nevi show high levels of the [p16.sup.INK4a] tumor suppressor gene product, which may protect from progression toward melanoma by p16-driven cell cycle arrest and senescence, inactivating mutations or deletions of the encoding CDKN2A gene may account for progression in some melanomas. (435,437-439) In addition, alterations in the activation of the PI3K-Akt pathway, which promotes survival and cell cycle entry of melanoma cells, may account for progression to melanoma. Approximately 20% to 40% of melanomas show loss or altered expression of the PTEN tumor suppressor gene, which acts as an upstream inhibitor of the PI3K-Akt pathway. (429,440-442) While inactivating mutations in PTEN were thought to be uncommon, (441,443) more recent data (eg, Hodis et al (444)) show a higher rate. There appears to be a correlation between PTEN and BRAF mutations in melanoma cell lines, suggesting possible synergism between the Ras/ Raf/MAPK and PI3K-Akt pathways. (445) This has been further supported by more recent data. While BRAF V600E expression in melanocytes of mice leads to melanocytic hyperplasia, invasive and metastatic melanoma development requires additional PTEN silencing. (446) Decreased PTEN expression or increased Akt expression is seen in human melanomas associated with nevi, while both nevi and melanomas show BRAF mutations. (447) Possible synergism has also been suggested for BRAF mutations and alterations of the TP53 gene, which leads to invasive melanoma. (448,449) However, p53 is not as commonly mutated in human melanoma when compared to other malignancies. (450)
Melanomas with wild-type BRAF can show mutations in the NRAS proto-oncogene, mainly in codon 61 (approximately 15% of all melanomas (429,431,451-455)). NRAS mutations leave the molecule in its active state, which results in increased signaling via the MAPK pathway mediated through RAF molecules. (428) However, NRAS also activates the PI3K pathway. (456) In addition, a recent study (457) has shown that the NRAS-mutant melanocytes also activate RAC1, a Rho GTPase, leading to increased survival and invasion. Similar to BRAF mutations, NRAS mutations do not appear to be sufficient, requiring additional alterations for malignant transformation. (428,433,458,459) While they can be seen in normal nevi, (435) they are also often seen in congenital nevi. (460)
Interestingly, the BRAF and NRAS mutations seen in melanoma do not carry a UV signature. Melanomas with BRAF mutations are less frequently found in melanomas occurring at sites of chronic sun damage, and more frequently in melanomas occurring in skin with intermittent acute sun damage. (426,432) NRAS-mutated melanoma does not show such a clear pattern, (426) although in some studies NRAS-mutated melanoma was more frequently found on the extremities and in older patients. (452,461,462) The findings on BRAF-mutated melanoma have been further supported by data showing that BRAF mutation-positive melanomas occur in a younger age group (usually younger than 55 years), without prominent sun damage, and more often involve the trunk and lower extremities, and less frequently in chronically sun-exposed areas such as the head and neck. (463,464) With regard to clinical behavior, BRAF mutation-positive melanomas may preferentially metastasize to regional lymph nodes as opposed to other sites.4 (65,466) With regard to prognosis, many studies on primary melanomas exhibiting BRAF and NRAS mutations showed no clear difference, although a recent large prospective study (467) showed significantly decreased survival for all stages for NRAS-driven melanoma, with a trend toward decreased survival in BRAF-driven melanoma. Studies (462,467-470) showed decreased survival for both NRAS- and BRAF-mutated melanoma at advanced stages.
Histologically, BRAF mutation-positive melanomas show nest formation of intraepidermal melanocytes, pagetoid spread of melanocytes, thickening of epidermis, and sharp demarcation. (465,466) As a result, BRAF mutations are often present in superficial spreading melanomas but are relatively rare in acral and lentigo maligna melanomas (426,464) (see also Table 2 for an overview of molecular alterations associated with certain melanoma subtypes). NRAS mutation-positive melanomas do not have very distinct histologic features but tend to have little or absent pagetoid spread. (465,466) Other studies (453,455,462,464,471) have suggested that NRAS mutations are more frequently seen in nodular melanomas. In addition, there is a correlation between increased tumor thickness and NRAS mutation, which mirrors the higher percentage of NRAS mutations in nodular melanoma. (452,461,467) Pure desmoplastic melanomas usually are negative for BRAF mutations, while limited data on NRAS mutations suggest a low frequency. (472-474)
Selective BRAF inhibitors for the treatment of metastatic melanoma exhibiting the BRAF V600E genotype are currently in development, with one compound (vemurafenib/PLX4032) showing promising initial response rates with improved short-term survival (475) and gaining US Food and Drug Administration approval in 2011. However, single-agent therapy may not lead to a prolonged sustained response, and various combination regimens, for example, with BRAF and MEK inhibitors, to overcome resistance mechanisms, are also being tested (see Sullivan and Flaherty (456) for an overview). No direct drugs have been successful against mutated NRAS up to now, (428,456) but some new MEK inhibitors or combination strategies may be effective in a subset of patients. (428)
Recent next-generation sequencing efforts uncovered additional Ras/Raf/MAPK pathway alterations in a subset of melanomas. Eight percent of melanomas showed gain-of-function mutations in the MAP2K1 (encoding MEK1) and MAP2K2 (encoding MEK2) genes, (476) resulting in constitutive activation of downstream ERK MAPK. In addition, 24% of melanomas were found to exhibit MAP3K5 (MAP kinase kinase kinase 5; synonyms: ASK1, MEKK5) and MAP3K9 (MAP kinase kinase kinase 9; synonyms: MlK1, MEKK9) mutations. (477)
KIT.--Lentigo maligna melanoma, which typically arises in chronically sun-damaged skin, shows differences in its molecular pathology, when compared to other subtypes such as superficial spreading or nodular melanoma. As mentioned above, BRAF mutations were less frequently found in melanomas occurring at sites of chronic sun damage (such as lentigo maligna melanoma), and more frequently (81%) in melanomas occurring in skin with intermittent acute sun damage (such as superficial spreading melanoma). (426) Accordingly, 28% of melanomas arising in chronically sun-damaged skin (and comparable fractions of mucosal and acral melanomas) were found to exhibit mutations or amplifications in the KIT gene encoding for the stem cell factor receptor tyrosine kinase. (478) However, another recent study (479) suggested melanomas arising in chronically sun-damaged skin much less commonly show KIT mutations. Upon ligand binding, Kit dimerizes, leading to autophosphorylation and downstream activation of the MAPK, PI3K-Akt, and JAK-STAT (janus kinase-signal transducer and activator of transcription) pathways. (480) Most commonly, mutations affect the region coding for the juxtamembrane domain of the Kit receptor, which lead to its dimerization and constitutive activation in the absence of stem cell factor, (481) creating a target for the imatinib tyrosine kinase inhibitor and other comparable agents. (482-484) While initial trials did not show a benefit in melanoma overall, newer trials involving patients with melanomas harboring KIT alterations show some promise for response to these targeted agents. (480,485-487) In addition, melanomas arising in chronically sun-damaged skin in the absence of BRAF or NRAS mutations more often show increased copy numbers of CDK4 and CCND1 (which encodes cyclin D1 at 11q13), which are downstream effectors of the Ras-Raf-MAPK pathway. (426)
Other Molecular Alterations.--Interestingly, lentigo maligna melanoma, together with melanomas occurring on chronic sun-damaged skin in general (as evidenced by solar elastosis and a head and neck location), shows a higher rate of p53 expression than melanomas arising in patients with a high nevus density or melanomas directly associated with nevi (which more commonly are superficial spreading melanomas), also supporting a different pathogenesis. (488)
Uveal melanomas do not show BRAF or NRAS alterations. Approximately 50% exhibit mutations in GNAQ (guanine nucleotide-binding protein Q polypeptide) or GNA11 (guanine nucleotide-binding protein a 11), which link G protein-coupled receptors to the MAPK and other signaling pathways. (480,489,490)
Micropthalmia-associated transcription factor regulates the differentiation of melanocytes and the maintenance of their progenitor cells. (491-493) Despite this role in differentiation and cell cycle arrest, the finding of increased copy numbers of MITF in an aggressive subset of melanomas suggests that it may also function as an oncogene, possibly in conjunction with BRAF mutation and p16 inactivation. (383,494) Melastatin (TRPM1), which is lost in a subset of melanomas with poor prognosis, is controlled by MITF. (383,495,496) Recently, it has been proposed that the tumor suppressive activity is not mediated by melastatin itself but rather by a microRNA (miR-211) hosted within an intron of melastatin. (497)
Several recent studies involving next-generation sequencing techniques have identified multiple additional recurrently mutated somatic genes. (444,476,498-501) Most of these studies show that the majority of mutated genes carry a UV signature, with more of these mutations seen in melanomas with chronic sun exposure, although it is difficult to exclude that many may represent UV-induced passenger mutations.
Novel driver mutations identified were found in the genes for serine phosphatase PPP6C and the small Ras-related Rho family GTPase Rac1. (444,499) A small subset of melanomas was found to show an RAC1 P29S mutation, which keeps Rac1 in its active, GTP-bound state. (444,499) Both studies found a recurrent mutation with a UV signature in RAC1 (among other novel driver mutations showing UV signatures in PPP6C and STK19). In addition, some melanomas negative for NRAS and BRAF mutations show mutations with putative loss of function in NF1, (444,499) which is a negative regulator of RAS and may confer MAPK activation, (502) or sometimes show mutations in HRAS, CRAF, MAP2K1, or KIT. Hodis et al (444) also showed that 44% of BRAF-driven melanomas have PTEN alterations. Krauthammer et al (499) showed that BRAFor NRAS-mutated melanomas often have losses of PTEN and/or CDKN2A mutations, or PPP6C mutations. Hodis et al (444) also found loss-of-function mutations in CDKN2A and TP53 mutations in a subset of melanomas.
Additional potential melanoma driver mutations identified in these efforts were found in PREX2 (PIP3-dependent rac exchange factor 2), a PTEN-interacting protein with negative regulatory function, and GRIN2A (glutamate receptor, ionotropic, N-methyl D-aspartate 2A) as well as TRRAP (transformation/transcription domain-associated protein). (498,501) Interestingly and very recently, mutations in a noncoding region of a gene were found in most melanomas, occurring in the promoter region of the TERT gene encoding for the catalytic subunit of telomerase, and leading to an increase in transcriptional activity. (503) Increased expression of telomerase could be involved in immortalization of melanocytes in the context of other oncogenic mutations.
Expression profiling of desmoplastic melanoma not only shows decreased expression of melanocyte differentiation antigens, consistent with the known decreased expression of these antigens by immunohistochemistry, but also upregulation of clusterin, along with neurotrophic and extracellular matrix factors, when compared to other melanoma types. (504)
Mice transgenic for the RET receptor tyrosine kinase, which binds a neurotrophic factor, develop melanomas. (505) More recently, a polymorphism in the region coding for the juxtamembrane region of the RET receptor tyrosine kinase was found in most desmoplastic melanomas, as compared to lower numbers in nondesmoplastic melanomas. (506) This polymorphism leads to increased downstream activity of the MAPK and PI3K/Akt pathways.
Recently, fluorescence in situ hybridization analysis with probes detecting aberrations on chromosomes 6, 7, 9, 10, and 11 was proposed as an additional diagnostic tool for melanoma. (507-509) For example, a combination of probes against 6p25 (RREB1), 6q23 (MYB), 11q13 (CCND1), and the centromeric region of chromosome 6 was reported to have a sensitivity of 83% and a specificity of 94% when compared to common nevi, dysplastic nevi, and Spitz nevi, with a 6p25 probe showing the highest specificity overall. (510) For melanoma occurring in chronically sun-damaged skin, a relative increase in 11q13 gain sensitivity to 35.7% and 41.7% was observed (versus 30.1% overall), while 6p25 gains were still the most common aberrations. The sensitivity of these fluorescence in situ hybridization probes appears to be lower for desmoplastic melanoma. (511) However, a limitation of all these studies is that they were performed on histologically unequivocal cases, and sensitivity and specificity in histologically equivocal cases may be lower. (512) Further study will be needed to establish the utility of these tests; however, it appears that the presence of multiple complex chromosomal aberrations in a histologically worrisome melanocytic lesion is highly suggestive of melanoma. For example, a study using comparative genomic hybridization found that while 96% of melanomas show at least 1 chromosomal aberration, only 13% of benign nevi do. (513) This technique has the advantage that it can be performed on paraffin-fixed tissue, although its use is currently still limited by high cost, time-consuming processing, and a requirement for relatively large amounts of tissue.
Please Note: Illustration(s) are not available due to copyright restrictions.
(1.) Rigel DS, Cockerell CJ, Carucci J, Wharton J. Actinic keratosis, basal cell carcinoma and squamous cell carcinoma. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. Maryland Heights, MO: Elsevier Mosby; 2008:1641-1660.
(2.) Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008; 8(10):743-754.
(3.) Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010; 60(5):277-300.
(4.) Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010; 375(9715):673-685.
(5.) Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005; 353(21):2262-2269.
(6.) Goldberg LH. Basal cell carcinoma. Lancet. 1996; 347(9002):663-667.
(7.) Brenn T, McKee PH. Tumors of the surface epithelium. In: McKee PH, Calonje E, Granter SR, eds. Pathology of the Skin With Clinical Correlations. 3rd ed. Maryland Heights, MO: Elsevier Mosby; 2005:1153-1240.
(8.) Kopf AW. Computer analysis of 3531 basal-cell carcinomas of the skin. J Dermatol. 1979; 6(5):267-281.
(9.) Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002; 147(1):41-47.
(10.) Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006; 19(suppl 2):S127-S147.
(11.) Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001; 63(1-3):8-18.
(12.) Emmett AJ. Surgical analysis and biological behaviour of 2277 basal cell carcinomas. Aust N Z J Surg. 1990; 60(11):855-863.
(13.) Miller SJ. Biology of basal cell carcinoma (part II). J Am Acad Dermatol. 1991; 24(2):161-175.
(14.) Miller SJ. Biology of basal cell carcinoma (part I). J Am Acad Dermatol. 1991; 24(1):1-13.
(15.) Roenigk RK, RatzJL, Bailin PL, Wheeland RG. Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol. 1986; 12(8):860-865.
(16.) Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994; 30(5, pt 1):774-778.
(17.) Gropper AB, Girouard SD, Hojman LP, et al. Metastatic basal cell carcinoma of the posterior neck: case report and review of the literature. J Cutan Pathol. 2012; 39(5):526-534.
(18.) Lang PG Jr, Maize JC. Histologic evolution of recurrent basal cell carcinoma and treatment implications. J Am Acad Dermatol. 1986; 14(2, pt 1): 186-196.
(19.) Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma: study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol. 1990; 23(6, pt 1):1118-1126.
(20.) Bowman PH, RatzJL, Knoepp TG, Barnes CJ, Finley EM. Basosquamous carcinoma. Dermatol Surg. 2003; 29(8):830-832.
(21.) Garcia C, Poletti E, Crowson AN. Basosquamous carcinoma. J Am Acad Dermatol. 2009; 60(1):137-143.
(22.) Hendrix JD Jr, Parlette HL. Micronodular basal cell carcinoma: a deceptive histologic subtype with frequent clinically undetected tumor extension. Arch Dermatol. 1996; 132(3):295-298.
(23.) Welsch MJ, Troiani BM, Hale L, DelTondo J, Helm KF, Clarke LE. Basal cell carcinoma characteristics as predictors of depth of invasion. J Am Acad Dermatol. 2012; 67(1):47-53.
(24.) Evans DG, Birch JM, Orton CI. Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome. Br J Neurosurg. 1991; 5(6):643-646.
(25.) Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore). 1987; 66(2):98-113.
(26.) Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin. 1995; 13(1):113-125.
(27.) Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997; 69(3):299-308.
(28.) Bazex A, Dupre A, Christol B. Follicular atrophoderma, baso-cellular proliferations and hypotrichosis [in French]. Ann Dermatol Syphiligr (Paris). 1966; 93(3):241-254.
(29.) Goeteyn M, Geerts ML, Kint A, De Weert J. The Bazex-Dupre-Christol syndrome. Arch Dermatol. 1994; 130(3):337-342.
(30.) Vabres P, Lacombe D, Rabinowitz LG, et al. The gene for Bazex-Dupre-Christol syndrome maps to chromosome Xq. J Invest Dermatol. 1995; 105(1):87-91.
(31.) Viksnins P, Berlin A. Follicular atrophoderma and basal cell carcinomas: the Bazex syndrome. Arch Dermatol. 1977; 113(7):948-951.
(32.) Ashinoff R, Jacobson M, Belsito DV. Rombo syndrome: a second case report and review. J Am Acad Dermatol. 1993; 28(6):1011-1014.
(33.) Michaelsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepithelio mas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereo!. 1981; 61(6):497-503.
(34.) Carney RG. Linear unilateral basal-cell nevus with comedones: reportofa case. AMA Arch Derm Syphilo!. 1952; 65(4):471-476.
(35.) Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992; 69(1):111-117.
(36.) Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996; 85(6):841-851.
(37.) Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996; 272(5268): 1668-1671.
(38.) Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science. 2004; 304(5678):1755-1759.
(39.) Murone M, Rosenthal A, de Sauvage FJ. Sonic hedgehog signaling by the patched-smoothened receptor complex. Curr Biol. 1999; 9(2):76-84.
(40.) Chidambaram A, Goldstein AM, Gailani MR, et al. Mutations in the human homologue of the Drosophila patched gene in Caucasian and African-American nevoid basal cell carcinoma syndrome patients. Cancer Res. 1996; 56(20):4599-4601.
(41.) Wicking C, Shanley S, Smyth I, et al. Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am J Hum Genet. 1997; 60(1):21-26.
(42.) Lindstrom E, Shimokawa T, Toftgard R, Zaphiropoulos PG. PTCH mutations: distribution and analyses. Hum Mutat. 2006; 27(3):215-219.
(43.) Jones EA, Sajid MI, Shenton A, Evans DG. Basal cell carcinomas in gorlin syndrome: a review of 202 patients. J Skin Cancer. 2011; 2011:217378.
(44.) Abuzahra F, Parren LJ, Wagenvoort T, et al. Linkage refinement of Bazex-Dupre-Christol syndrome to an 11.4 Mb interval on chromosome Xq25-27.1. Br J Dermatol. 2011.
(45.) Adolphe C, Hetherington R, Ellis T, Wainwright B. Patched! functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 2006; 66(4):20812088.
(46.) Hutchin ME, Kariapper MS, Grachtchouk M, et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005; 19(2):214-223.
(47.) Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol. 1998; 110(6):885-888.
(48.) Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996; 14(1):78-81.
(49.) Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005; 152(1):43-51.
(50.) Teh MT, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res. 2005; 65(19):8597-8603.
(51.) Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998; 391(6662):90-92.
(52.) Ashton KJ, Weinstein SR, Maguire DJ, Griffiths LR. Molecular cytogenetic analysis of basal cell carcinoma DNA using comparative genomic hybridization. J Invest Dermatol. 2001; 117(3):683-686.
(53.) Dahmane N, Lee J, Robins P, Heller P, Ruiz i Altaba A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature. 1997; 389(6653):876-881.
(54.) Asplund A, Sivertsson A, Backvall H, Ahmadian A, LundebergJ, Ponten F. Genetic mosaicism in basal cell carcinoma. Exp Dermatol. 2005; 14(8):593-600.
(55.) Liboutet M, Portela M, Delestaing G, et al. MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas. J Invest Dermatol. 2006; 126(7):1510-1517.
(56.) Regl G, Kasper M, Schnidar H, et al. Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res. 2004; 64(21):7724-7731.
(57.) Barnes EA, Heidtman KJ, Donoghue DJ. Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC. Oncogene. 2005; 24(5): 902-915.
(58.) Iwasaki JK, Srivastava D, Moy RL, Lin HJ, Kouba DJ. The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol. 2012; 66(5):e167-e178.
(59.) Bigelow RL, Chari NS, Unden AB, et al. Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem. 2004; 279(2):1197-1205.
(60.) Yang SH, Andl T, Grachtchouk V, et al. Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. Nat Genet. 2008; 40(9):1130-1135.
(61.) El-Bahrawy M, El-Masry N, Alison M, Poulsom R, Fallowfield M. Expression of beta-catenin in basal cell carcinoma. Br J Dermatol. 2003; 148(5): 964-970.
(62.) Yamazaki F, Aragane Y, Kawada A, Tezuka T. Immunohistochemical detection for nuclear beta-catenin in sporadic basal cell carcinoma. Br J Dermatol. 2001; 145(5):771-777.
(63.) Schnidar H, Eberl M, Klingler S, et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res. 2009; 69(4):1284-1292.
(64.) Aszterbaum M, Epstein J, Oro A, et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med. 1999; 5(11):1285-1291.
(65.) Grachtchouk M, Mo R, Yu S, et al. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet. 2000; 24(3):216-217.
(66.) Nilsson M, Unden AB, Krause D, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci USA. 2000; 97(7):3438-3443.
(67.) Oro AE, Higgins KM, Hu Z, BonifasJM, Epstein EH Jr, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 1997; 276(5313): 817-821.
(68.) Ling G, Ahmadian A, Persson A, et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene. 2001; 20(53):7770-7778.
(69.) Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA. 1993; 90(9):4216-4220.
(70.) Ponten F, Berg C, Ahmadian A, et al. Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene. 1997; 15(9):1059-1067.
(71.) Tabata H, Nagano T, RayAJ, Flanagan N, Birch-MacHin MA, ReesJL. Low frequency of genetic change in p53 immunopositive clones in human epidermis. J Invest Dermatol. 1999; 113(6):972-976.
(72.) Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 2001; 61(2): 513-516.
(73.) Cretnik M, Poje G, Musani V, et al. Involvement of p16 and PTCH in pathogenesis of melanoma and basal cell carcinoma. Int J Oncol. 2009; 34(4): 1045-1050.
(74.) Kanellou P, Zaravinos A, Zioga M, Spandidos DA. Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma. Br J Dermatol. 2009; 160(6):1215-1221.
(75.) Rees JL. The genetics of sun sensitivity in humans. Am J Hum Genet. 2004; 75(5):739-751.
(76.) Sturm RA. Skin colour and skin cancer: MC1R, the genetic link. Melanoma Res. 2002; 12(5):405-416.
(77.) Bastiaens MT, ter Huurne JA, Kielich C, et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet. 2001; 68(4):884-894.
(78.) Box NF, Duffy DL, Irving RE, et al. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol. 2001; 116(2):224-229.
(79.) Gudbjartsson DF, Sulem P, Stacey SN, et al. ASIPand TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat
Genet. 2008; 40(7):886-891.
(80.) Stacey SN, Sulem P, Masson G, et al. New common variants affecting susceptibility to basal cell carcinoma. Nat Genet. 2009; 41(8):909-914.
(81.) Kasper M, Jaks V, Hohl D, Toftgard R. Basal cell carcinoma--molecular biology and potential new therapies. J Clin Invest. 2012; 122(2):455-463.
(82.) Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366(23):2171-2179.
(83.) Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012; 366(23):2180-2188.
(84.) Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001; 344(13):975-983.
(85.) McGuire JF, Ge NN, Dyson S. Nonmelanoma skin cancer of the head and neck, I: histopathology and clinical behavior. Am J Otolaryngol. 2009; 30(2):121-133.
(86.) McCall CO, Chen SC. Squamous cell carcinoma of the legs in African Americans. J Am Acad Dermatol. 2002; 47(4):524-529.
(87.) Mora RG, Perniciaro C. Cancer of the skin in blacks, I: a review of 163 black patients with cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1981; 5(5):535-543.
(88.) Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol. 1992; 26(3, pt 2):467-484.
(89.) Melnikova VO, Ananthaswamy HN. Cellular and molecular events leading to the development of skin cancer. Mutat Res. 2005; 571(1-2):91-106.
(90.) Blohme I, Larko O. Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. Acta Derm Venereol. 1990; 70(6):491-494.
(91.) Dyall-Smith D, Trowell H, Mark A, Dyall-Smith M. Cutaneous squamous cell carcinomas and papillomaviruses in renal transplant recipients: a clinical and molecular biological study. J Dermatol Sci. 1991; 2(3):139-146.
(92.) Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol. 2003; 139(3):301-306.
(93.) Frierson HF Jr, Deutsch BD, Levine PA. Clinicopathologic features of cutaneous squamous cell carcinomas of the head and neck in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol. 1988; 19(12):1397-1402.
(94.) Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol. 2002; 138(6):758-763.
(95.) Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001; 45(6):953-956.
(96.) Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000; 42(l):23-24.
(97.) Moller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol. 1979; 115(6):703-705.
(98.) Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. J Am Acad Dermatol. 1992; 26(6): 976-990.
(99.) Breuninger H, Black B, Rassner G. Microstaging of squamous cell carcinomas. Am J Clin Pathol. 1990; 94(5):624-627.
(100.) Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008; 9(8):713-720.
(101.) Lehmann AR, Bridges BA. Sunlight-induced cancer: some new aspects and implications of the xeroderma pigmentosum model. Br J Dermatol. 1990; 122(suppl 35):115-119.
(102.) Cleaver JE, Thomas GH. Clinical syndromes associated with DNA repair deficiency and enhanced sun sensitivity. Arch Dermatol. 1993; 129(3):348-350.
(103.) Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum: cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol. 1987; 123(2):241-250.
(104.) Shumrick KA, Coldiron B. Genetic syndromes associated with skin cancer. Otolaryngol Clin North Am. 1993; 26(1):117-137.
(105.) Roytta M, Anttinen A. Xeroderma pigmentosum with neurological abnormalities: a clinical and neuropathological study. Acta Neurol Scand. 1986; 73(2):191-199.
(106.) Okulicz JF, Shah RS, Schwartz RA, Janniger CK. Oculocutaneous albinism. J Eur Acad Dermatol Venereol. 2003; 17(3):251-256.
(107.) Kaspar TA, Wagner RF Jr, Jablonska S, Niimura M, Tyring SK. Prognosis and treatment of advanced squamous cell carcinoma secondary to epidermodysplasia verruciformis: a worldwide analysis of 11 patients. J Dermatol Surg Oncol. 1991; 17(3):237-240.
(108.) Berneburg M, Lehmann AR. Xeroderma pigmentosum and related disorders: defects in DNA repair and transcription. Adv Genet. 2001; 43:71-102.
(109.) Cleaver JE. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer. 2005; 5(7):564-573.
(110.) Asahina H, Kuraoka I, Shirakawa M, et al. The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage. Mutat Res. 1994; 315(3):229-237.
(111.) Tanaka K, Miura N, Satokata I, et al. Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain. Nature. 1990; 348(6296):73-76.
(112.) Johnson RE, Kondratick CM, Prakash S, Prakash L. hRAD30 mutations in the variant form of xeroderma pigmentosum. Science. 1999; 285(5425):263-265.
(113.) Masutani C, Kusumoto R, Yamada A, et al. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature. 1999; 399(6737):700-704.
(114.) Oetting WS, King RA. Molecular basis of type I (tyrosinase-related) oculocutaneous albinism: mutations and polymorphisms of the human tyrosinase gene. Hum Mutat. 1993; 2(1):1-6.
(115.) Spritz RA. Molecular genetics of oculocutaneous albinism. Semin Dermatol. 1993; 12(3): 167-172.
(116.) Ramsay M, Colman MA, Stevens G, et al. The tyrosinase-positive oculocutaneous albinism locus maps to chromosome 15q11.2-q12. Am J Hum Genet. 1992; 51(4):879-884.
(117.) Stevens G, van Beukering J, Jenkins T, Ramsay M. An intragenic deletion of the P gene is the common mutation causing tyrosinase-positive oculocutaneous albinism in southern African Negroids. Am J Hum Genet. 1995; 56(3):586-591.
(118.) Oetting WS, Garrett SS, Brott M, King RA. P gene mutations associated with oculocutaneous albinism type II (OCA2). Hum Mutat. 2005; 25(3):323.
(119.) Puri N, Gardner JM, Brilliant MH. Aberrant pH of melanosomes in pink-eyed dilution (p) mutant melanocytes. J Invest Dermatol. 2000; 115(4):607-613.
(120.) King RA, Willaert RK, Schmidt RM, et al. MC1R mutations modify the classic phenotype of oculocutaneous albinism type 2 (OCA2). Am J Hum Genet. 2003; 73(3):638-645.
(121.) Manga P, KrombergJG, Box NF, Sturm RA, Jenkins T, Ramsay M. Rufous oculocutaneous albinism in southern African Blacks is caused by mutations in the TYRP1 gene. Am J Hum Genet. 1997; 61(5):1095-1101.
(122.) Scheinfeld NS. Syndromic albinism: a review of genetics and phenotypes. Dermatol Online J. 2003; 9(5):5.
(123.) Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet. 2002; 32(4):579-581.
(124.) Ramoz N, Taieb A, Rueda LA, et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J Invest Dermatol. 2000; 114(6):1148-1153.
(125.) Lane DP. Cancer. p53, guardian of the genome. Nature. 1992; 358(6381): 15-16.
(126.) Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-331.
(127.) Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991; 88(22):10124-10128.
(128.) Campbell C, Quinn AG, Ro YS, Angus B, Rees JL. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol. 1993; 100(6):746-748.
(129.) Kubo Y, Urano Y, Yoshimoto K, et al. p53 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. J Invest Dermatol. 1994; 102(4):440-444.
(130.) Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994; 372(6508):773-776.
(131.) Li G, Tron V, Ho V. Induction of squamous cell carcinoma in p53-deficient mice after ultraviolet irradiation. J Invest Dermatol. 1998; 110(1):72-75.
(132.) Backvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F. Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res. 2005; 571(1-2):65-79.
(133.) Barzilai A, Lyakhovitsky A, Trau H, Fogel M, Huszar M. Expression of p53 in the evolution of squamous cell carcinoma: correlation with the histology of the lesion. J Am Acad Dermatol. 2007; 57(4):669-676.
(134.) Berg RJ, van Kranen HJ, Rebel HG, et al. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. ProcNatlAcadSci USA. 1996; 93(1):274-278.
(135.) Mudgil AV, Segal N, Andriani F, Wang Y, Fusenig NE, Garlick JA. Ultraviolet B irradiation induces expansion of intraepithelial tumor cells in a tissue model of early cancer progression. J Invest Dermatol. 2003; 121(1):191 -197.
(136.) Zhang W, Chen S. EGR-1, a UV-inducible gene in p53(-/-) mouse cells. Exp Cell Res. 2001; 266(1):21-30.
(137.) Jin C, Jin Y, Wennerberg J, Akervall J, Dictor M, Mertens F. Karyotypic heterogeneity and clonal evolution in squamous cell carcinomas of the head and neck. Cancer Genet Cytogenet. 2002; 132(2):85-96.
(138.) Ananthaswamy HN, Price JE, Goldberg LH, Bales ES. Detection and identification of activated oncogenes in human skin cancers occurring on sun-exposed body sites. Cancer Res. 1988; 48(12):3341-3346.
(139.) Pelisson I, Soler C, Pechoux C, et al. c-myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions. J Dermatol Sci. 1992; 3(1):56-67.
(140.) Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog. 1991; 4(3):196-202.
(141.) Ronai ZA, Okin E, Weinstein IB. Ultraviolet light induces the expression of oncogenes in rat fibroblast and human keratinocyte cells. Oncogene. 1988; 2(2):201-204.
(142.) Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol. 1995; 131(7):796-800.
(143.) van der Schroeff JG, Evers LM, Boot AJ, BosJL. Ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin. J Invest Dermatol. 1990; 94(4):423-425.
(144.) Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004; 91(2):355-358.
(145.) Su F, Viros A, MilagreC, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366(3): 207-215.
(146.) Ratushny V, GoberMD, Hick R, RidkyTW, SeykoraJT. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest. 2012; 122(2):464-472.
(147.) Zhao L, Li W, Marshall C, et al. Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53. Cancer Res. 2009; 69(24): 9439-9447.
(148.) Mortier L, Marchetti P, Delaporte E, et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16(INK4a) tumor suppressor. Cancer Lett. 2002; 176(2): 205-214.
(149.) Pacifico A, Goldberg LH, Peris K, Chimenti S, Leone G, Ananthaswamy HN. Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers. Br J Dermatol. 2008; 158(2):291-297.
(150.) Liu B, Park E, Zhu F, et al. A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci USA. 2006; 103(46):17202-17207.
(151.) Wang NJ, Sanborn Z, Arnett KL, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA. 2011; 108(43):17761-17766.
(152.) Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009; 137(2):216-233.
(153.) Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell. 2009; 16(1):55-66.
(154.) Dotto GP. Notch tumor suppressor function. Oncogene. 2008; 27(38): 5115-5123.
(155.) Nicolas M, Wolfer A, Raj K, et al. Notchl functions as a tumor suppressor in mouse skin. Nat Genet. 2003; 33(3):416-421.
(156.) Agarwal RP, Handler SD, Matthews MR, Carpentieri D. Pilomatrixoma of the head and neck in children. Otolaryngol Head Neck Surg. 2001; 125(5):510-515.
(157.) Stransky N, EgloffAM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333(6046):1157-1160.
(158.) ChevilleJC, Bromley C, Argenyi ZB. Trisomy 7 in keratoacanthoma and squamous cell carcinoma detected by fluorescence in-situ hybridization. J Cutan Pathol. 1995; 22(6):546-550.
(159.) Clausen OP, Beigi M, Bolund L, et al. Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol. 2002; 119(6):1367-1372.
(160.) Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas: a comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol. 2006; 126(10):2308-2315.
(161.) Beer TW, Drury P, Heenan PJ. Atypical fibroxanthoma: a histological and immunohistochemical review of 171 cases. Am J Dermatopathol. 2010; 32(6): 533-540.
(162.) Fretzin DF, Helwig EB. Atypical fibroxanthoma of the skin: a clinico-pathologic study of 140 cases. Cancer. 1973; 31(6):1541-1552.
(163.) lorizzo LJ III, Brown MD. Atypical fibroxanthoma: a review of the literature. Dermatol Surg. 2011; 37(2):146-157.
(164.) Mirza B, Weedon D. Atypical fibroxanthoma: a clinicopathological study of 89 cases. Australas J Dermatol. 2005; 46(4):235-238.
(165.) Cooper JZ, Newman SR, Scott GA, Brown MD. Metastasizing atypical fibroxanthoma (cutaneous malignant histiocytoma): report of five cases [discussion in Dermatol Surg. 2005; 31(2):225].Dermatol Surg. 2005; 31(2):221-225.
(166.) Helwig EB, May D. Atypical fibroxanthoma of the skin with metastasis. Cancer. 1986; 57(2):368-376.
(167.) Kemp JD, Stenn KS, Arons M, Fischer J. Metastasizing atypical fibroxanthoma: coexistence with chronic lymphocytic leukemia. Arch Dermatol. 1978; 114(10):1533-1535.
(168.) Lum DJ, King AR. Peritoneal metastases from an atypical fibroxanthoma. Am J Surg Pathol. 2006; 30(8):1041-1046.
(169.) Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol. 2012; 36(9):1317-1326.
(170.) Dotto JE, Glusac EJ. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2006; 33(6):413-417.
(171.) Gleason BC, Calder KB, Cibull TL, et al. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma. J Cutan Pathol. 2009; 36(5):543-547.
(172.) Dei Tos AP, Maestro R, Doglioni C, et al. Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol. 1994; 145(1):11-17.
(173.) Sakamoto A, Oda Y, Itakura E, et al. H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma. Hum Pathol. 2001;
(174.) Dilek FH, Akpolat N, Metin A, Ugras S. Atypical fibroxanthoma of the skin and the lower lip in xeroderma pigmentosum. Br J Dermatol. 2000; 143(3): 618-620.
(175.) Patterson JW, Jordan WP Jr. Atypical fibroxanthoma in a patient with xeroderma pigmentosum. Arch Dermatol. 1987; 123(8):1066-1070.
(176.) Youssef N, Vabres P, Buisson T, Brousse N, Fraitag S. Two unusual tumors in a patient with xeroderma pigmentosum: atypical fibroxanthoma and basosquamous carcinoma. J Cutan Pathol. 1999; 26(9):430-435.
(177.) Mihic-Probst D, ZhaoJ, Saremaslani P, et al. CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma. Anticancer Res. 2004; 24(1):19-26.
(178.) Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. 2005; 89(1):1-4.
(179.) Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010; 37(1):20-27.
(180.) Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, Lupton GP, Graham JH. Merkel cell carcinoma: analysis o clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol. 1997; 37(5, pt 1):734-739.
(181.) TarantolaTI, Vallow LA, Halyard MY, et al. Prognostic factors in Merkel cell carcinoma: analysis of 240 cases. J Am Acad Dermatol. 2013; 68(3):425 432.
(182.) Hitchcock CL, Bland KI, Laney RG III, Franzini D, Harris B, Copeland EM III. Neuroendocrine (Merkel cell) carcinoma of the skin: its natural history, diagnosis, and treatment. Ann Surg. 1988; 207(2):201-207.
(183.) Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008; 58(3):375-381.
(184.) Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005; 23(10):2300-2309.
(185.) Lim CS, Whalley D, Haydu LE, et al. Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. Ann Surg Oncol. 2012; 19(1 1):3325-3334.
(186.) Sibley RK, Dahl D. Primary neuroendocrine (Merkel cell?) carcinoma of the skin, II: an immunocytochemical study of 21 cases. Am J Surg Pathol. 1985; 9(2):109-116.
(187.) Sibley RK, Dehner LP, Rosai J. Primary neuroendocrine (Merkel cell?) carcinoma of the skin, I: a clinicopathologic and ultrastructural study of 43 cases. Am J Surg Pathol. 1985; 9(2):95-108.
(188.) Poulsen M. Merkel-cell carcinoma of the skin. Lancet Oncol. 2004; 5(10): 593-599.
(189.) Tilling T, Moll I. Which are the cells of origin in merkel cell carcinoma [published online ahead of print December 13, 2012]. J Skin Cancer. doi:10. 1155/2012/680410.
(190.) ChanJK, Suster S, Wenig BM, Tsang WY, Chan JB, Lau AL. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol. 1997; 21(2):226-234.
(191.) Miettinen M, Lehto VP, Virtanen I, Asko-Seljavaara S, Pitkanen J, Dahl D. Neuroendocrine carcinoma of the skin (Merkel cell carcinoma): ultrastructural and immunohistochemical demonstration of neurofilaments. Ultrastruct Pathol. 1983; 4(2-3):219-225.
(192.) Asioli S, Righi A, de Biase D, et al. Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) Merkel cell carcinomas. Mod Pathol. 2011; 24(11):1451-1461.
(193.) Bichakjian CK, Lowe L, Lao CD, et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer. 2007; 110(1): 1-12.
(194.) Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008; 319(5866): 1096-1100.
(195.) Lunder EJ, Stern RS. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med. 1998; 339(17):1247-1248.
(196.) Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev. 1999; 8(2):153-158.
(197.) Urbatsch A, Sams WM Jr, Urist MM, Sturdivant R. Merkel cell carcinoma occurring in renal transplant patients. J Am Acad Dermatol. 1999; 41(2, pt2):289 291.
(198.) Van Gele M, Kaghad M, Leonard JH, et al. Mutation analysis of P73 and TP53 in Merkel cell carcinoma. Br J Cancer. 2000; 82(4):823-826.
(199.) Gancberg D, Feoli F, Hamels J, et al. Trisomy 6 in Merkel cell carcinoma: a recurrent chromosomal aberration. Histopathology. 2000; 37(5):445-451.
(200.) Harnett PR, Kearsley JH, Hayward Nk, Dracopoli NC, Kefford RF. Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma: a marker of neural crest origins? Cancer Genet Cytogenet. 1991; 54(1):109-113.
(201.) Leonard JH, Hayard N. Loss of heterozygosity of chromosome 13 in Merkel cell carcinoma. Genes Chromosomes Cancer. 1997; 20(1):93-97.
(202.) Van Gele M, Van Roy N, Ronan SG, et al. Molecular analysis of 1p36 breakpoints in two Merkel cell carcinomas. Genes Chromosomes Cancer. 1998; 23(1):67-71.
(203.) Paulson KG, Lemos BD, Feng B, et al. Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol. 2009; 129(6):1547-1555.
(204.) Lassacher A, Heitzer E, Kerl H, Wolf P. p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. J Invest Dermatol. 2008; 128(7):1788-1796.
(205.) Su LD, Fullen DR, Lowe L, Uherova P, Schnitzer B, Valdez R. CD117 (KIT receptor) expression in Merkel cell carcinoma. Am J Dermatopathol. 2002; 24(4): 289-293.
(206.) Andea AA, Patel R, Ponnazhagan S, et al. Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status. Hum Pathol. 2010; 41(10):1405-1412.
(207.) Kartha RV, Sundram UN. Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis. Mod Pathol. 2008; 21(2): 96-104.
(208.) Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene--implications for treatment with imatinib mesylate. J Cutan Pathol. 2007; 34(4):324-329.
(209.) Samlowski WE, Moon J, Tuthill RJ, et al. A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). Am J Clin Oncol. 2010; 33(5):495-499.
(210.) Houben R, Michel B, Vetter-Kauczok CS, et al. Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J Invest Dermatol. 2006; 126(5):1135-1142.
(211.) Liu S, Daa T, Kashima K, Kondoh Y, Yokoyama S. The Wnt-signaling pathway is not implicated in tumorigenesis of Merkel cell carcinoma. J Cutan Pathol. 2007; 34(1):22-26.
(212.) Popp S, Waltering S, Herbst C, Moll I, Boukamp P. UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer. 2002; 99(3):352-360.
(213.) Van Gele M, Leonard JH, Van Roy N, Cook AL, De Paepe A, Speleman F. Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel cell carcinoma. Int J Cancer. 2001; 92(3):409-413.
(214.) Hafner C, Houben R, Baeurle A, et al. Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One. 2012; 7(2):e31255.
(215.) Nardi V, Song Y, Santamaria-Barria JA, et al. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012; 18(5):1227-1236.
(216.) Shuda M, Feng H, Kwun HJ, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA. 2008; 105(42):16272-16277.
(217.) Becker JC, Houben R, Ugurel S, Trefzer U, Pfohler C, Schrama D. MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol. 2009; 129(1):248-250.
(218.) Busam KJ, Jungbluth AA, Rekthman N, et al. Merkel cell polyomavirus expression in merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas. Am J Surg Pathol. 2009; 33(9):1378-1385.
(219.) Kassem A, Schopflin A, Diaz C, et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res. 2008; 68(13):5009-5013.
(220.) Andres C, Puchta U, Sander CA, Ruzicka T, Flaig MJ. Prevalence of Merkel cell polyomavirus DNA in cutaneous lymphomas, pseudolymphomas, and inflammatory skin diseases. Am J Dermatopathol. 2010; 32(6):593-598.
(221.) Dworkin AM, Tseng SY, Allain DC, Iwenofu OH, Peters SB, Toland AE. Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol. 2009; 129(12):2868-2874.
(222.) Kassem A, Technau K, Kurz AK, et al. Merkel cell polyomavirus sequences are frequently detected in nonmelanoma skin cancer of immunosuppressed patients. Int J Cancer. 2009; 125(2):356-361.
(223.) Katano H, Ito H, Suzuki Y, et al. Detection of Merkel cell polyomavirus in Merkel cell carcinoma and Kaposi's sarcoma. J Med Virol. 2009; 81(11):1951-1958.
(224.) Sihto H, Kukko H, Koljonen V, Sankila R, Bohling T, Joensuu H. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst. 2009; 101(13):938-945.
(225.) Bhatia K, GoedertJJ, Modali R, Preiss L, Ayers LW. Merkel cell carcinoma subgroups by Merkel cell polyomavirus DNA relative abundance and oncogene expression. Int J Cancer. 2010; 126(9):2240-2246.
(226.) Hall BJ, Pincus LB, Yu SS, Oh DH, Wilson AR, McCalmont TH. Immunohistochemical prognostication of Merkel cell carcinoma: p63 expression but not polyomavirus status correlates with outcome. J Cutan Pathol. 2012; 39(10):911-917.
(227.) Schrama D, Peitsch WK, Zapatka M, et al. Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. J Invest Dermatol. 2011; 131(8):1631-1638.
(228.) Sihto H, Kukko H, Koljonen V, Sankila R, Bohling T, Joensuu H. Merkel cell polyomavirus infection, large Tantigen, retinoblastoma protein and outcome in merkel cell carcinoma. Clin Cancer Res. 2011; 17(14):4806-4813.
(229.) Brownstein MH, Shapiro L. Trichilemmoma: analysis of 40 new cases. Arch Dermatol. 1973; 107(6):866-869.
(230.) Chan P, White SW, Pierson DL, Rodman OG. Trichilemmoma. J Dermatol SurgOncol. 1979; 5(1):58-59.
(231.) Castilla EA, Bergfeld WF, Ormsby A. Trichilemmoma and syringocystadenoma papilliferum arising in naevus sebaceous. Pathology. 2002; 34(2):196-197.
(232.) Hidayat AA, Font RL. Trichilemmoma of eyelid and eyebrow: a clinicopathologic study of 31 cases. Arch Ophthalmol. 1980; 98(5):844-847.
(233.) Boscaino A, Terracciano LM, Donofrio V, Ferrara G, De Rosa G. Tricholemmal carcinoma: a study of seven cases. J Cutan Pathol. 1992; 19(2): 94-99.
(234.) Swanson PE, Marrogi AJ, Williams DJ, Cherwitz DL, Wick MR. Tricholemmal carcinoma: clinicopathologic study of 10 cases. J Cutan Pathol. 1992; 19(2):100-109.
(235.) Wong TY, Suster S. Tricholemmal carcinoma: a clinicopathologic study of 13 cases. Am J Dermatopathol. 1994; 16(5):463-473.
(236.) Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000; 37(11):828-830.
(237.) Salem OS, Steck WD. Cowden's disease (multiple hamartoma and neoplasia syndrome): a case report and review of the English literature. J Am Acad Dermatol. 1983; 8(5):686-696.
(238.) Fistarol SK, Anliker MD, Itin PH. Cowden disease or multiple hamartoma syndrome--cutaneous clue to internal malignancy. Eur J Dermatol. 2002; 12(5): 411-421.
(239.) Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986; 29(3):222-233.
(240.) Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012; 18(2):400-407.
(241.) Brownstein MH, Mehregan AH, Bikowski JB, Lupulescu A, Patterson JC. The dermatopathology of Cowden's syndrome. Br J Dermatol. 1979; 100(6):667-673.
(242.) Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer. 1978; 41(6):2393-2398.
(243.) Starink TM, Meijer CJ, Brownstein MH. The cutaneous pathology of Cowden's disease: new findings. J Cutan Pathol. 1985; 12(2):83-93.
(244.) Starink TM, Hausman R. The cutaneous pathology of extrafacial lesions in Cowden's disease. J Cutan Pathol. 1984; 11(5):338-344.
(245.) Starink TM, Hausman R. The cutaneous pathology of facial lesions in Cowden's disease. J Cutan Pathol. 1984; 11(5):331-337.
(246.) Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet. 2008; 16(11):1289-1300.
(247.) Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-1947.
(248.) Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997; 16(1):64-67.
(249.) Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet. 1996; 13(1):114-116.
(250.) Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003; 22(3):183198.
(251.) Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet. 2002; 70(4):829-844.
(252.) HobertJA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009; 11(10):687-694.
(253.) Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotypephenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998; 7(3):507-515.
(254.) Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet. 2003; 73(2):404-411.
(255.) Pezzolesi MG, Platzer P, Waite KA, Eng C. Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet. 2008; 82(5):1141-1149.
(256.) Trotman LC, Wang X, Alimonti A, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007; 128(1):141-156.
(257.) Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene. 2008; 27(41):5443-5453.
(258.) Orloff MS, He X, Peterson C, et al. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet. 2013; 92(1):76-80.
(259.) Al-Zaid T, Ditelberg JS, Prieto VG, et al. Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. J Cutan Pathol. 2012; 39(5):493-499.
(260.) Zhou X, Hampel H, Thiele H, et al. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet. 2001; 358(9277):210-211.
(261.) Cho YJ, Liang P. Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci U S A. 2008; 105(14):5396-5401.
(262.) Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA. 2010; 304(24):2724-2731.
(263.) BatsakisJG. Dermal eccrine cylindroma. Ann Otol RhinolLaryngol. 1989; 98(12):991-992.
(264.) Crain RC, Helwig EB. Dermal cylindroma (dermal eccrine cylindroma). Am J Clin Pathol. 1961; 35:504-515.
(265.) Cotton DW, Braye SG. Dermal cylindromas originate from the eccrine sweat gland. Br J Dermatol. 1984; 111(1):53-61.
(266.) Demirkesen C, Hoede N, Moll R. Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins. J Cutan Pathol. 1995; 22(6):518-535.
(267.) Durani BK, Kurzen H, Jaeckel A, Kuner N, Naeher H, Hartschuh W. Malignant transformation of multiple dermal cylindromas. Br J Dermatol. 2001; 145(4):653-656.
(268.) Gerretsen AL, van der Putte SC, Deenstra W, van Vloten WA. Cutaneous cylindroma with malignant transformation. Cancer. 1993; 72(5):1618-1623.
(269.) Garat H, Loche F, Gorguet B, Rumeau H, Lamant L, Bazex J. Brooke-Spiegler syndrome [in French]. Ann Dermatol Venereol. 1999; 126(6-7):513-517.
(270.) Gerretsen AL, Beemer FA, Deenstra W, Hennekam FA, van Vloten WA. Familial cutaneous cylindromas: investigations in five generations of a family. J Am Acad Dermatol. 1995; 33(2):199-206.
(271.) Rasmussen JE. A syndrome of trichoepitheliomas, milia, and cylindromas. Arch Dermatol. 1975; 111(5):610-614.
(272.) Szepietowski JC, Wasik F, Szybejko-Machaj G, Bieniek A, Schwartz RA. Brooke-Spiegler syndrome. J Eur Acad Dermatol Venereol. 2001; 15(4):346-349.
(273.) Berberian BJ, Sulica VI, Kao GF. Familial multiple eccrine spiradenomas with cylindromatous features associated with epithelioma adenoides cysticum of Brooke. Cutis. 1990; 46(1):46-50.
(274.) Kim C, Kovich OI, DosikJ. Brooke-Spiegler syndrome. DermatolOnline J. 2007; 13(1):10.
(275.) Welch JP, Wells RS, Kerr CB. Ancell-Spiegler cylindromas (turban tumours) and Brooke-Fordyce trichoepitheliomas: evidence for a single genetic entity. J Med Genet. 1968; 5(1):29-35.
(276.) Ferrandiz C, Campo E, Baumann E. Dermal cylindromas (turban tumour) and eccrine spiradenomas in a patient with membranous basal cell adenoma of the parotid gland. J Cutan Pathol. 1985; 12(1):72-79.
(277.) Jungehulsing M, Wagner M, Damm M. Turban tumour with involvement of the parotid gland. J Laryngol Otol. 1999; 113(8):779-783.
(278.) Reingold IM, Keasbey LE, Graham JH. Multicentric dermal-type cylindromas of the parotid glands in a patient with florid turban tumor. Cancer. 1977; 40(4):1702-1710.
(279.) Biernat W, Biernat S. Cutaneous adnexal carcinoma arising within a solitary cylindroma-spiradenoma. Am J Dermatopathol. 1996; 18(1):77-82.
(280.) Hyman BA, Scheithauer BW, Weiland LH, Irons GB. Membranous basal cell adenoma of the parotid gland: malignant transformation in a patient with multiple dermal cylindromas. Arch Pathol Lab Med. 1988; 112(2):209-211.
(281.) Pizinger K, Michal M. Malignant cylindroma in Brooke-Spiegler syndrome. Dermatology. 2000; 201(3):255-257.
(282.) Biggs PJ, Wooster R, Ford D, et al. Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene. Nat Cenet. 1995; 1l(4):441-443.
(283.) Biggs PJ, Chapman P, Lakhani SR, Burn J, Stratton MR. The cylindromatosis gene (cyldl) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas. Oncogene. 1996; 12(6):13 75-1377.
(284.) Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Cenet. 2000; 25(2):160-165.
(285.) Leonard N, Chaggar R, Jones C, Takahashi M, Nikitopoulou A, Lakhani SR. Loss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours. J Clin Pathol. 2001; 54(9):689-692.
(286.) Takahashi M, Rapley E, Biggs PJ, et al. Linkage and LOH studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and refine the CYLD locus on chromosome 16q12-q13. Hum Cenet. 2000; 106(1):58-65.
(287.) Choi HR, BatsakisJG, Callender DL, Prieto VG, Luna MA, El-Naggar AK. Molecular analysis of chromosome 16q regions in dermal analogue tumors of salivary glands: a genetic link to dermal cylindroma? Am J Surg Pathol. 2002; 26(6):778-783.
(288.) Grossmann P, Vanecek T, Steiner P, et al. Novel and recurrent germline and somatic mutations in a cohort of 67 patients from 48 families with Brooke-Spiegler Syndrome including the phenotypic variant of multiple familial trichoepitheliomas and correlation with the histopathologic findings in 379 biopsy specimens. Am J Dermatopathol. 2013; 35(1):34-44.
(289.) Salhi A, Bornholdt D, Oeffner F, et al. Multiple familial trichoepithelioma caused by mutations in the cylindromatosis tumor suppressor gene. Cancer Res. 2004; 64(15):5113-5117.
(290.) Poblete Gutierrez P, Eggermann T, Holler D, et al. Phenotype diversity in familial cylindromatosis: a frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of skin appendages. J Invest Dermatol. 2002; 119(2):527-531.
(291.) Scheinfeld N, Hu G, Gill M, Austin C, Celebi JT. Identification of a recurrent mutation in the CYLD gene in Brooke-Spiegler syndrome. Clin Exp Dermatol. 2003; 28(5):539-541.
(292.) Sima R, Vanecek T, Kacerovska D, et al. Brooke-Spiegler syndrome: report of 10 patients from 8 families with novel germline mutations: evidence of diverse somatic mutations in the same patient regardless of tumor type. Diagn MolPathol. 2010; 19(2):83-91.
(293.) Bowen S, Gill M, Lee DA, et al. Mutations in the CYLD gene in BrookeSpiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation. J Invest Dermatol. 2005; 124(5): 919-920.
(294.) Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000; 18:621-663.
(295.) Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002; 2(10):725-734.
(296.) Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature. 2003; 424(6950):797-801.
(297.) Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature. 2003; 424(6950):801-805.
(298.) Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature. 2003; 424(6950):793-796.
(299.) Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA. 2007; 104(21):8869-8874.
(300.) Reiley W, Zhang M, Sun SC. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem. 2004; 279(53):55161-55167.
(301.) Tauriello DV, Haegebarth A, Kuper I, et al. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell. 2010; 37(5):607-619.
(302.) Wickstrom SA, Masoumi KC, Khochbin S, Fassler R, Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J. 2010; 29(1):131-144.
(303.) Rulon DB, Helwig EB. Cutaneous sebaceous neoplasms. Cancer. 1974; 33(1):82-102.
(304.) Shalin SC, Lyle S, Calonje E, Lazar AJ. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010; 56(1):133-147.
(305.) Misago N, Mihara I, Ansai S, Narisawa Y. Sebaceoma and related neoplasms with sebaceous differentiation: a clinicopathologic study of 30 cases. Am J Dermatopathol. 2002; 24(4):294-304.
(306.) Troy JL, Ackerman AB. Sebaceoma: a distinctive benign neoplasm of adnexal epithelium differentiating toward sebaceous cells. Am J Dermatopathol. 1984; 6(1):7-13.
(307.) Nelson BR, Hamlet KR, Gillard M, Railan D, Johnson TM. Sebaceous carcinoma [quiz in J Am Acad Dermatol. 1995; 33(1):16-18]. J Am Acad Dermatol. 1995; 33(1):1-15.
(308.) Moreno C, Jacyk WK, Judd MJ, Requena L. Highly aggressive extraocular sebaceous carcinoma. Am J Dermatopathol. 2001; 23(5):450-455.
(309.) Barana D, van der Klift H, Wijnen J, et al. Spectrum of genetic alterations in Muir-Torre syndrome is the same as in HNPCC. Am J Med Cenet A. 2004; 125A(3):318-319.
(310.) Muir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg. 1967; 54(3):191-195.
(311.) Paraf F, Sasseville D, Watters AK, et al. Clinicopathological relevance of the association between gastrointestinal and sebaceous neoplasms: the Muir-Torre syndrome. Hum Pathol. 1995; 26(4):422-427.
(312.) South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008; 100(4):277-281.
(313.) Torre D. Multiple sebaceous tumors. Arch Dermatol. 1968; 98(5):549-551.
(314.) Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003; 138(7):560-570.
(315.) Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991; 34(5):424-425.
(316.) Curry ML, Eng W, Lund K, Paek D, Cockerell CJ. Muir-Torre syndrome: role of the dermatopathologist in diagnosis. Am J Dermatopathol. 2004; 26(3): 217-221.
(317.) Finan MC, Connolly SM. Sebaceous gland tumors and systemic disease: a clinicopathologic analysis. Medicine (Baltimore). 1984; 63(4):232-242.
(318.) Dores GM, Curtis RE, Toro JR, Devesa SS, Fraumeni JF Jr. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer. 2008; 113(12):3372-3381.
(319.) Abbott JJ, Hernandez-Rios P, Amirkhan RH, Hoang MP. Cystic sebaceous neoplasms in Muir-Torre syndrome. Arch Pathol Lab Med. 2003; 127(5):614-617.
(320.) Banse-Kupin L, Morales A, Barlow M. Torre's syndrome: report of two cases and review of the literature. J Am Acad Dermatol. 1984; 10(5, pt 1):803-817.
(321.) Cesinaro AM, Ubiali A, Sighinolfi P, Trentini GP, Gentili F, Facchetti F. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. Am J Dermatopathol. 2007; 29(4):351-358.
(322.) Rutten A, Burgdorf W, Hugel H, et al. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study. Am J Dermatopathol. 1999; 21(5):405-413.
(323.) Singh RS, Grayson W, Redston M, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008; 32(6):936-942.
(324.) Fishel R, Ewel A, Lee S, Lescoe MK, Griffith J. Binding of mismatched microsatellite DNA sequences by the human MSH2 protein. Science. 1994; 266(5189):1403-1405.
(325.) Prolla TA, Pang Q, Alani E, Kolodner RD, Liskay RM. MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast. Science. 1994; 265(5175):1091-1093.
(326.) Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. CancerRes. 1998; 58(22):5248-5257.
(327.) Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Cenet. 1999; 36(11):801-818.
(328.) Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer. 2003; 2:41.
(329.) Honchel R, Halling KC, Schaid DJ, Pittelkow M, Thibodeau SN. Microsatellite instability in Muir-Torre syndrome. Cancer Res. 1994; 54(5): 1159-1163.
(330.) Kruse R, Lamberti C, Wang Y, et al. Is the mismatch repair deficient type of Muir-Torre syndrome confined to mutations in the hMSH2 gene? Hum Cenet. 1996; 98(6):747-750.
(331.) Murphy HR, Armstrong R, Cairns D, Greenhalgh KL. Muir-Torre Syndrome: expanding the genotype and phenotype-a further family with a MSH6 mutation. Fam Cancer. 2008; 7(3):255-257.
(332.) Entius MM, Keller JJ, Drillenburg P, Kuypers KC, Giardiello FM, Offerhaus GJ. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res. 2000; 6(5):1784-1789.
(333.) Mathiak M, Rutten A, Mangold E, et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol. 2002; 26(3):338-343.
(334.) de la Chapelle A. Testing tumors for microsatellite instability. Eur J Hum Cenet. 1999; 7(4):407-408.
(335.) Frazier ML, Sinicrope FA, Amos CI, et al. Loci for efficient detection of microsatellite instability in hereditary non-polyposis colorectal cancer. Oncol Rep. 1999; 6(3):497-505.
(336.) Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res. 1997; 57(2):300-303.
(337.) Southey MC, Young MA, Whitty J, et al. Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesis. Am J Surg Pathol. 2001; 25(7): 936-941.
(338.) Cabral ES, AuerbachA, Killian JK, Barrett TL, Cassarino DS. Distinction of benign sebaceous proliferations from sebaceous carcinomas by immunohistochemistry. Am J Dermatopathol. 2006; 28(6):465-471.
(339.) Gonzalez-Fernandez F, Kaltreider SA, Patnaik BD, et al. Sebaceous carcinoma: tumor progression through mutational inactivation of p53. Ophthalmology. 1998; 105(3):497-506.
(340.) Hayashi N, Furihata M, Ohtsuki Y, Ueno H. Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid. Virchows Arch. 1994; 424(5):503-509.
(341.) Kiyosaki K, Nakada C, Hijiya N, et al. Analysis of p53 mutations and the expression of p53 and p21WAF1/CIP1 protein in 15 cases of sebaceous carcinoma of the eyelid. Invest Ophthalmol Vis Sci. 2010; 51(1):7-11.
(342.) McBride SR, Leonard N, Reynolds NJ. Loss of p21(WAF1) compartmentalisation in sebaceous carcinoma compared with sebaceous hyperplasia and sebaceous adenoma. J Clin Pathol. 2002; 55(10):763-766.
(343.) Niemann C, Owens DM, Hulsken J, Birchmeier W, Watt FM. Expression of DeltaNLef1 in mouse epidermis results in differentiation of hair follicles into squamous epidermal cysts and formation of skin tumours. Development. 2002; 129(1):95-109.
(344.) Niemann C, Unden AB, Lyle S, Zouboulis ChC, Toftgard R, Watt FM. Indian hedgehog and beta-catenin signaling: role in the sebaceous lineage of normal and neoplastic mammalian epidermis. Proc Natl Acad Sci U S A. 2003; 100(suppl 1):11873-11880.
(345.) Takeda H, Lyle S, Lazar AJ, Zouboulis CC, Smyth I, Watt FM. Human sebaceous tumors harbor inactivating mutations in LEF1. Nat Med. 2006; 12(4): 395-397.
(346.) Goldberg M, Rummelt C, Foja S, Holbach LM, Ballhausen WG. Different genetic pathways in the development of periocular sebaceous gland carcinomas in presumptive Muir-Torre syndrome patients. Hum Mutat. 2006; 27(2):155-162.
(347.) Holbach LM, vonMollerA, Decker C, Junemann AG, Rummelt-Hofmann C, Ballhausen WG. Loss of fragile histidine triad (FHIT) expression and microsatellite instability in periocular sebaceous gland carcinoma in patients with Muir-Torre syndrome. Am J Ophthalmol. 2002; 134(1):147-148.
(348.) Julian CG, Bowers PW. A clinical review of 209 pilomatricomas. J Am Acad Dermatol. 1998; 39(2, pt 1):191-195.
(349.) Lan MY, Lan MC, Ho CY, Li WY, Lin CZ. Pilomatricoma of the head and neck: a retrospective review of 179 cases. Arch Otolaryngol Head Neck Surg. 2003; 129(12):1327-1330.
(350.) Marrogi AJ, Wick MR, Dehner LP. Pilomatrical neoplasms in children and young adults. Am J Dermatopathol. 1992; 14(2):87-94.
(351.) O'Connor N, Patel M, Umar T, Macpherson DW, Ethunandan M. Head and neck pilomatricoma: an analysis of 201 cases. Br J Oral Maxillofac Surg. 2011; 49(5):354-358.
(352.) Thomas RW, Perkins JA, RuegemerJL, MunarettoJA. Surgical excision of pilomatrixoma of the head and neck: a retrospective review of 26 cases. Ear Nose ThroatJ. 1999; 78(8):544-546.
(353.) Berberian BJ, Colonna TM, Battaglia M, Sulica VI. Multiple pilomatricomas in association with myotonic dystrophy and a family history of melanoma. J Am Acad Dermatol. 1997; 37(2, pt 1):268-269.
(354.) Cambiaghi S, Ermacora E, Brusasco A, Canzi L, Caputo R. Multiple pilomatricomas in Rubinstein-Taybi syndrome: a case report. Pediatr Dermatol. 1994; 11(1):21-25.
(355.) Cooper PH, Fechner RE. Pilomatricoma-like changes in the epidermal cysts of Gardner's syndrome. J Am Acad Dermatol. 1983; 8(5):639-644.
(356.) Wood S, Nguyen D, Hutton K, Dickson W. Pilomatricomas in Turner syndrome. Pediatr Dermatol. 2008; 25(4):449-451.
(357.) Lazar AJ, Calonje E, Grayson W, et al. Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. J Cutan Pathol. 2005; 32(2):148-157.
(358.) Sau P, Lupton GP, Graham JH. Pilomatrix carcinoma. Cancer. 1993; 71(8): 2491-2498.
(359.) Nishioka M, Tanemura A, Yamanaka T, et al. Pilomatrix carcinoma arising from pilomatricoma after 10-year senescent period: immunohistochemical analysis. J Dermatol. 2010; 37(8):735-739.
(360.) Kaddu S, Soyer HP, Cerroni L, Salmhofer W, Hodl S. Clinical and histopathologic spectrum of pilomatricomas in adults. Int J Dermatol. 1994; 33(10):705-708.
(361.) Hardisson D, Linares MD, Cuevas-Santos J, Contreras F. Pilomatrix carcinoma: a clinicopathologic study of six cases and review of the literature. Am J Dermatopathol. 2001; 23(5):394-401.
(362.) Chan EF, Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet. 1999; 21(4):410-413.
(363.) Kajino Y, Yamaguchi A, Hashimoto N, Matsuura A, Sato N, Kikuchi K. beta-Catenin gene mutation in human hair follicle-related tumors. Pathol Int. 2001; 51(7):543-548.
(364.) Moreno-Bueno G, Gamallo C, Perez-Gallego L, Contreras F, Palacios J. beta-catenin expression in pilomatrixomas: relationship with beta-catenin gene mutations and comparison with beta-catenin expression in normal hair follicles. Br J Dermatol. 2001; 145(4):576-581.
(365.) Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta. 2008; 1778(3): 660-669.
(366.) Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691-701.
(367.) van EsJH, Barker N, Clevers H. You Wntsome, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev. 2003; 13(1):28-33.
(368.) Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-480.
(369.) Bienz M. The subcellular destinations of APC proteins. Nat Rev Mol Cell Biol. 2002; 3(5):328-338.
(370.) Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996; 382(6592):638-642.
(371.) MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1):9-26.
(372.) He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998; 281(5382):1509-1512.
(373.) Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398(6726):422-426.
(374.) Xu X, Lyle S, Liu Y, Solky B, Cotsarelis G. Differential expression of cyclin D1 in the human hair follicle. Am J Pathol. 2003; 163(3):969-978.
(375.) Gat U, DasGupta R, Degenstein L, Fuchs E. De novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell. 1998; 95(5):605-614.
(376.) Krahl D, Sellheyer K. Basal cell carcinoma and pilomatrixoma mirror human follicular embryogenesis as reflected by their differential expression patterns of SOX9 and beta-catenin. Br J Dermatol. 2010; 162(6):1294-1301.
(377.) Agoston AT, Liang CW, Richkind KE, Fletcher JA, Vargas SO. Trisomy 18 is a consistent cytogenetic feature in pilomatricoma. Mod Pathol. 2010; 23(8):1147-1150.
(378.) Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004; 150(2):179-185.
(379.) National Cancer Institute. Surveillance Epidemiology and End Results: SEER stat fact sheets: melanoma of the skin. http://seer.cancer.gov/statfacts/html/ melan.html. Accessed May 10, 2013.
(380.) Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies: The International Melanoma Analysis Group (IMAGE). Int J Cancer. 1995; 62(4):367-376.
(381.) Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma, II: sun exposure. Eur J Cancer. 2005; 41(1):45-60.
(382.) Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma, III: family history, actinic damage and phenotypic factors. Eur J Cancer. 2005; 41(14):2040-2059.
(383.) Miller AJ, Mihm MC Jr. Melanoma. N EnglJMed. 2006; 355(1):51-65.
(384.) de Snoo FA, Kroon MW, Bergman W, et al. From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients. J Am Acad Dermatol. 2007; 56(5):748-752.
(385.) Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma, I: common and atypical naevi. Eur J Cancer. 2005; 41(1): 28-44.
(386.) Stolz W, Schmoeckel C, Landthaler M, Braun-Falco O. Association of early malignant melanoma with nevocytic nevi. Cancer. 1989; 63(3):550-555.
(387.) Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol. 2003; 139(3):282-288.
(388.) Gachon J, Beaulieu P, Sei JF, et al. First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol. 2005; 141 (4):434-438.
(389.) Rigel DS, Friedman RJ. The rationale of the ABCDs of early melanoma. J Am Acad Dermatol. 1993; 29(6):1060-1061.
(390.) Clark WH Jr, Mihm MC Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol. 1969; 55(1):39-67.
(391.) Newell GR, Sider JG, Bergfelt L, Kripke ML. Incidence of cutaneous melanoma in the United States by histology with special reference to the face. Cancer Res. 1988; 48(17):5036-5041.
(392.) Holman CD, Armstrong BK, Heenan PJ. Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst. 1986; 76(3):403-414.
(393.) Lea CS, Scotto JA, Buffler PA, Fine J, Barnhill RL, Berwick M. Ambient UVB and melanoma risk in the United States: a case-control analysis. Ann Epidemiol. 2007; 17(6):447-453.
(394.) Nelemans PJ, Groenendal H, Kiemeney LA, Rampen FH, Ruiter DJ, Verbeek AL. Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect. 1993; 101(3):252-255.
(395.) Jain S, Allen PW. Desmoplastic malignant melanoma and its variants: a study of 45 cases. Am J Surg Pathol. 1989; 13(5):358-373.
(396.) Quinn MJ, Crotty KA, Thompson JF, Coates AS, O'Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer. 1998; 83(6):1128-1135.
(397.) Wasif N, Gray RJ, Pockaj BA. Desmoplastic melanoma-the step-child in the melanoma family? J Surg Oncol. 2011; 103(2):158-162.
(398.) Anderson WF, Pfeiffer RM, Tucker MA, Rosenberg PS. Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma. Cancer. 2009; 115(18):4176-4185.
(399.) Averbook BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: implications on the future of cancer staging. Surgery. 2002; 132(4):589-602.
(400.) Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer. 1995; 75(10):2484-2491.
(401.) Sahin S, Rao B, Kopf AW, et al. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration ofa prognostic model. Cancer. 1997; 80(8):1426-1431.
(402.) Stidham KR, Johnson JL, Seigler HF. Survival superiority of females with melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg. 1994; 129(3):316-324.
(403.) Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol. 2008; 144(4):515-521.
(404.) Langford FP, Fisher SR, Molter DW, Seigler HF. Lentigo maligna melanoma of the head and neck. Laryngoscope. 1993; 103(5):520-524.
(405.) O'Brien CJ, Coates AS, Petersen-Schaefer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg. 1991; 162(4):310-314.
(406.) Busam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol. 2005; 12(2):92-102.
(407.) Murali R, Shaw HM, Lai K, et al. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. Cancer. 2010; 116(17):4130-4138.
(408.) Baer SC, Schultz D, Synnestvedt M, Elder DE. Desmoplasia and neurotropism: prognostic variables in patients with stage I melanoma. Cancer. 1995; 76(11):2242-2247.
(409.) Busam KJ, Mujumdar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol. 2004; 28(11):1518-1525.
(410.) Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 28 cases. Cancer. 1995; 75(2):478-494.
(411.) Skelton HG, Smith KJ, Laskin WB, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol. 1995; 32(5, pt 1):717-725.
(412.) Clark WH Jr, Ainsworth AM, Bernardino EA, Yang CH, Mihm CM Jr, Reed RJ. The developmental biology of primary human malignant melanomas. Semin Oncol. 1975; 2(2):83-103.
(413.) Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-6206.
(414.) Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970; 172(5):902-908.
(415.) Flotte TJ, Mihm MCJr. Lentigo maligna and malignant melanoma in situ, lentigo maligna type. Hum Pathol. 1999; 30(5):533-536.
(416.) Bataille V. Genetic epidemiology of melanoma. Eur J Cancer. 2003; 39(10):1341-1347.
(417.) Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992; 258(5085):1148-1152.
(418.) Greene MH. The genetics of hereditary melanoma and nevi: 1998 update. Cancer. 1999; 86(11 suppl):2464-2477.
(419.) Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994; 8(1):15-21.
(420.) Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366(6456): 704-707.
(421.) Ranade K, Hussussian CJ, Sikorski RS, et al. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995; 10(1):114-116.
(422.) Begg CB, Zhang ZF, Sun M, Herr HW, Schantz SP. Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. Am J Epidemiol. 1995; 142(6):653-665.
(423.) Berwick M, Orlow I, Hummer AJ, et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev. 2006; 15(8):1520-1525.
(424.) Kanetsky PA, Rebbeck TR, Hummer AJ, et al. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res. 2006; 66(18):9330-9337.
(425.) Busca R, Abbe P, Mantoux F, et al. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J. 2000; 19(12):2900-2910.
(426.) Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20):2135-2147.
(427.) Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-954.
(428.) Fedorenko IV, Gibney GT, Smalley KS. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management [published online ahead of print October 15, 2012]. Oncogene. doi:10.1038/onc.2012.453.
(429.) Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006; 126(1):154-160.
(430.) Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat. 2007; 28(6):578-588.
(431.) Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol. 2011; 223(2):241-250.
(432.) Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003; 95(24):1878-1890.
(433.) Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003; 9(17):6483-6488.
(434.) Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012; 26(11):1131-1155.
(435.) Pollock PM, Cohen-Solal K, Sood R, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet. 2003; 34(1):108-112.
(436.) Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer. 2004; 111(5):705-710.
(437.) Keller-Melchior R, Schmidt R, Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol. 1998; 110(6):932-938.
(438.) Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436(7051):720724.
(439.) Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components. J Cutan MedSurg. 1999; 3(6): 293-297.
(440.) Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res. 2005; 11(14):5153-5157.
(441.) Pollock PM, Walker GJ, GlendeningJM, et al. PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res. 2002; 12(6):565-575.
(442.) Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene. 1998; 16(26):3397-3402.
(443.) Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008; 68(3):664-673.
(444.) Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2):251-263.
(445.) Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004; 122(2):337-341.
(446.) Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009; 41(5):544-552.
(447.) Vredeveld LC, Possik PA, Smit MA, et al. Abrogation of BRAFV600Einduced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012; 26(10):1055-1069.
(448.) Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet. 2005; 37(7):745-749.
(449.) Patton EE, Widlund HR, Kutok JL, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma Curr Biol. 2005; 15(3):249-254.
(450.) Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer. 2003; 3(8):559-570.
(451.) Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol. 1994; 131(1):72-77.
(452.) Edlundh-Rose E, Egyhazi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006; 16(6):471-478.
(453.) Jafari M, Papp T, Kirchner S, et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol. 1995; 121(1):23-30.
(454.) Reifenberger J, Knobbe CB, Sterzinger AA, et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer. 2004; 109(3):377-384.
(455.) van Elsas A, Zerp SF, van der Flier S, et al. Relevance of ultravioletinduced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol. 1996; 149(3):883-893.
(456.) Sullivan RJ, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene. 2013; 32(19):2373-2379.
(457.) Li A, Ma Y, Jin M, et al. Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J Invest Dermatol. 2012; 132(11):2610-2621.
(458.) Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol. 2001; 117(6):1483-1489.
(459.) Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res. 2002; 8(11):3468-3474.
(460.) Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol. 2007; 127(1):179-182.
(461.) Ellerhorst JA, Greene VR, Ekmekcioglu S, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011; 17(2):229-235.
(462.) Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012; 118(16): 4014-4023.
(463.) Bauer J, Buttner P, Murali R, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011; 24(2):345-351.
(464.) Liu W, Kelly JW, Trivett M, et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol. 2007; 127(4):900-905.
(465.) Broekaert SM, Roy R, Okamoto I, et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 2010; 23(6):763-770.
(466.) Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008; 5(6):e120.
(467.) Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011; 24(4):666-672.
(468.) Houben R, Becker JC, Kappel A, et al. Constitutive activation of the RasRaf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004; 3(1):6.
(469.) Mann GJ, Pupo GM, Campain AE, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol. 2013; 133(2): 509-517.
(470.) Moreau S, Saiag P, Aegerter P, et al. Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol. 2012; 19(13):4314-4321.
(471.) Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a metaanalysis. Br J Dermatol. 2011; 164(4):776-784.
(472.) Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer. 2005; 103(4):788-792.
(473.) Kim J, Lazar AJ, Davies MA, et al. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol. 2012; 39(9):821-825.
(474.) Miller DD, Emley A, Yang S, et al. Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal. Mod Pathol. 2012; 25(4):505-515.
(475.) Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-2516.
(476.) Nikolaev SI, Rimoldi D, Iseli C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 2012; 44(2):133-139.
(477.) Stark MS, Woods SL, Gartside MG, et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet. 2012; 44(2):165-169.
(478.) Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24(26):4340-4346.
(479.) Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer. 2010; 102(8):1219-1223.
(480.) Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol. 2011; 12(9); 913-922.
(481.) Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M, Ronnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene. 1999; 18(40):5546-5553.
(482.) Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002; 1(12):1115-1124.
(483.) Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23):4342-4349.
(484.) Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 2004; 279(30):31655-31663.
(485.) Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011; 305(22):2327-2334.
(486.) GuoJ, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011; 29(21):2904-2909.
(487.) Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012; 18(5):1457-1463.
(488.) Purdue MP, From L, Kahn HJ, et al. Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma. Int J Cancer. 2005; 117(3): 486-493.
(489.) Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009; 457(7229):599-602.
(490.) Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-2199.
(491.) Hodgkinson CA, Moore KJ, Nakayama A, et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell. 1993; 74(2):395-404.
(492.) Nishimura EK, Granter SR, Fisher DE. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science. 2005; 307(5710):720-724.
(493.) Widlund HR, Fisher DE. Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene. 2003; 22(20):3035-3041.
(494.) Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005; 436(7047):117-122.
(495.) Duncan LM, Deeds J, Hunter J, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res. 1998; 58(7):1515-1520.
(496.) Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res. 2004; 64(2):509-516.
(497.) Levy C, Khaled M, Iliopoulos D, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 2010; 40(5): 841- 849.
(498.) Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012; 485(7399):502-506.
(499.) Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012; 44(9):1006-1014.
(500.) Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010; 463(7278):191-196.
(501.) Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011; 43(5):442-446.
(502.) Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010; 10(12) 842- 857.
(503.) Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339(6122):957-959.
(504.) Busam KJ, Kucukgol D, Eastlake-Wade S, Frosina D, Delgado R, Jungbluth AA. Clusterin expression in primary and metastatic melanoma. J Cutan Pathol. 2006; 33(9):619-623.
(505.) Kato M, Takahashi M, Akhand AA, et al. Transgenic mouse model for skin malignant melanoma. Oncogene. 1998; 17(14):1885-1888.
(506.) Narita N, TanemuraA, Murali R, et al. Functional RETG691S polymorphism in cutaneous malignant melanoma. Oncogene. 2009; 28(34):3058-3068.
(507.) Bastian BC. Molecular cytogenetics as a diagnostic tool for typing melanocytic tumors. Recent Results Cancer Res. 2002; 160:92-99.
(508.) Casorzo L, Luzzi C, Nardacchione A, Picciotto F, Pisacane A, Risio M. Fluorescence in situ hybridization (FISH) evaluation of chromosomes 6, 7, 9 and 10 throughout human melanocytic tumorigenesis. Melanoma Res. 2005; 15(3): 155-160.
(509.) Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol. 2009; 33(8):1146-1156.
(510.) Gerami P, Mafee M, Lurtsbarapa T, Guitart J, Haghighat Z, Newman M. Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes. Arch Dermatol. 2010; 146(3):273-278.
(511.) Gerami P, Beilfuss B, Haghighat Z, Fang Y, Jhanwar S, Busam KJ. Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi. J Cutan Pathol. 2011; 38(4):329-334.
(512.) Gaiser T, Kutzner H, Palmedo G, et al. Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up. ModPathol. 2010; 23(3):413-419.
(513.) Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003; 163(5):1765-1770.
Stefan Kraft, MD; Scott R. Granter, MD
Accepted for publication May 22, 2013.
From the Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (Dr Kraft); and the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Dr Granter).
The authors have no relevant financial interest in the products or companies described in this article.
Reprints: Stefan Kraft, MD, Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52 20246 Hamburg, Germany (e-mail: email@example.com).
Caption: Figure 1. Basal cell carcinoma (BCC). A, Nodular BCC: This lesion shows classical features with lobules of basaloid tumor cells with peripheral palisading and cleft formation between lobules and the mucin-rich stroma. B, Superficial BCC: Small basaloid tumor nests are attached to the epidermis. C, Infiltrative BCC: Small irregularly shaped nests and strands of tumor cells without prominent palisading and clefting (hematoxylin-eosin, original magnifications X40 [A], X100 [B], and X400 [C]).
Caption: Figure 2. Hedgehog (HH) signaling and aberrations in basal cell nevus syndrome (BCNS) and basal cell carcinoma (BCC): Under normal conditions (left side), PTCH1 (patched 1) suppresses SMO (smoothened). In the presence of sonic hedgehog (SHH), this inhibition is relieved and SMO internalizes, relieving inhibition of GLI transcription factors by suppressor of fused (SUFU). GLI factors then translocate to the nucleus and induce transcription of target genes. In BCNS and sporadic BCC, inactivating mutations and/or loss of PTCH1, or activating mutations of SMO, lead to constitutive activation of GLI transcription factors, expression of target genes, and cellular transformation. Alterations in TP53 and CDKN2A (cyclin-dependent kinase inhibitor 2A) may play a supportive role, and alterations in pigmentation genes, such as MC1R (melanocortin receptor 1), increase the risk for these events.
Caption: Figure 3. Invasive squamous cell carcinoma. Nests of large keratinizing cells with eosinophilic cytoplasm, nuclear atypia, and mitotic activity (hematoxylin-eosin, original magnification X400).
Caption: Figure 4. Actinic keratosis. Predominantly basally located atypical keratinocytes with large, irregular, hyperchromatic nuclei (hematoxylineosin, original magnification X400).
Caption: Figure 5. Atypical fibroxanthoma. Pleomorphic and multinucleated tumor cells (hematoxylin-eosin, original magnification X400).
Caption: Figure 6. Merkel cell carcinoma. A, Predominantly dermal nodule consisting of small round blue cells. B, The cells have a high nuclear to cytoplasmic ratio and watery, pale chromatin with nuclear molding. C, Lymphovascular invasion is a common feature. D, Perinuclear dotlike reactivity for CK20 is characteristic (hematoxylin-eosin, original magnifications X20 [A], X400 [B], X100 [C], and X200 [D]).
Caption: Figure 7. Trichilemmoma. A, Lobules of small uniform cells with peripheral palisading. B, The bland-appearing cells exhibit a clear cytoplasm owing to glycogen accumulation (hematoxylin-eosin, original magnifications X40 [A] and X400 [B]).
Caption: Figure 8. Cylindroma. Tumor lobules with a prominent basement membrane are arranged in a jigsaw pattern (hematoxylin-eosin, original magnification X100).
Caption: Figure 9. Sebaceous neoplasms. A, Sebaceous adenoma: The periphery of the lobule shows immature basaloid cells and the center, mature sebaceous cells. B, Sebaceoma. Basaloid cells are more prominent and intermixed with sebaceous cells. C, Sebaceous carcinoma. There is significant pleomorphism and mitotic activity (hematoxylin-eosin, original magnifications X200 [A], X100 [B], and X400 [C]).
Caption: Figure 10. Microsatellite instability assessed by polymerase chain reaction (PCR) and capillary electrophoresis for the genomic marker BAT 26. A, Product from normal tissue (1 arrow). B, Amplification of tumor DNA yields a novel PCR product indicating microsatellite instability (2 arrows).
Caption: Figure 11. Pilomatricoma. Transition from peripheral basaloid cells to central "ghost cells" (hematoxylin-eosin, original magnification X200).
Caption: Figure 12. Wnt (Wingless and INT-1)/[beta]-catenin pathway. Left panel: Under inactive conditions, cytoplasmic [beta]-catenin ([beta] Cat) is recruited to a "destruction complex" organized by axin. N-terminal phosphorylation of [beta] Cat by casein kinase (CK) and glycogen synthase kinase (GSK) leads to ubiquitinylation and proteasomal degradation of [beta] Cat. Lef-1 (lymphoid enhancer-binding factor 1) acts as a transcriptional repressor in the presence of TLE (Groucho) and histone deacetylase (HDAC). Middle panel: Extracellular Wnt ligands bind to LRP5/6 and Frizzled, leading to recruitment of Dishevelled (DSH), which then recruits axin and the destruction complex, followed by its degradation. [beta]-Catenin accumulates in the cytoplasm and translocates to the nucleus where it activates Lef-1-mediated transcription of genes. Right panel: In pilomatricoma, point mutations alter the N-terminal phosphorylation sites in p Cat, which then cannot be phosphorylated, inhibiting its degradation and leading to accumulation in the cytoplasm. [beta]-Catenin and Lef-1-mediated transcription of target genes includes cyclin D1. Abbreviations: APC, adenomatous polyposis coli; LRP, low-density-lipoprotein receptor-related protein.
Caption: Figure 13. Melanoma subtypes more common on sun-exposed skin of the head and neck. A, Lentigo maligna melanoma in situ. The cells show a cytoplasmic retraction artifact and large angulated nuclei. B, Desmoplastic melanoma. Atypical spindle cells in a dense fibrocollagenous stroma (hematoxylin-eosin, original magnifications X400 [A] and X200 [B]).
Table 1. Genetic Abnormalities in Adnexal Tumors Gene Location Associated Condition CTNNB1 3p21 * Pilomatricoma ([beta]-catenin) * Pilomatrix carcinoma CYLD 16q12-13 * Familial cylindromatosis * Cylindroma FHIT (fragile 3p14 * Sebaceous carcinoma histidine triad) KLLN (killin) 10q23 * Cowden syndrome (multiple trichilemmomas) LEF1 4q23-25 * Differentiated sporadic sebaceous neoplasms MSH2, MLH1, MSH6 2p21, 3p21, 2p16 * Muir-Torre syndrome (multiple sebaceous neoplasms) PTEN (phosphatase 10q23 * Cowden syndrome (multiple and tensin homolog) trichilemmomas) TP53 17p13 * Sporadic sebaceous carcinoma Gene Gene Function CTNNB1 * Proto-oncogene in Wnt signaling ([beta]-catenin) * Activates Lef-1 transcription factor CYLD * Tumor suppressor * Deubiquitinylation * NF-[kappa]B inhibition * Wnt/[beta]-catenin inhibition FHIT (fragile * Tumor suppressor histidine triad) * Inhibits Wnt/[beta]-catenin KLLN (killin) * Tumor suppressor * p53 target * Inhibits DNA replication (S-phase arrest) LEF1 * Proto-oncogene * Transcription factor in Wnt pathway * Hair follicle morphogenesis MSH2, MLH1, MSH6 * DNA mismatch repair PTEN (phosphatase * Tumor suppressor and tensin homolog) * Phosphatase * Inhibits PI3K/Akt pathway * Inhibits MAPK pathway TP53 * Tumor suppressor * Inhibits cell cycle progression * Proapoptotic * Induces DNA repair Gene Common Genetic Abnormalities CTNNB1 Mutations in regions encoding phosphorylation ([beta]-catenin) sites lead to stabilization CYLD Mutations lead to truncated product FHIT (fragile Intragenic deletion and promoter methylation histidine triad) KLLN (killin) Promoter hypermethylation LEF1 Double nucleotide substitutions impair Lef-1 binding to [beta]-catenin and transcriptional function MSH2, MLH1, MSH6 Germline mutations lead to truncated product, subsequent microsatellite instability PTEN (phosphatase Frameshift, nonsense, and missense mutations; and tensin homolog) less commonly, promoter hypermethylation TP53 Point mutations; likely no "UV signature" Abbreviations: LEF-1, lymphoid enhancer-binding factor 1; MAPK, mitogen-activated protein kinase; NF-[kappa]B, nuclear factor [kappa]B; PI3K, phosphoinositide-3 kinase; Wnt, Wingless and INT-1. Table 2. Genetic Abnormalities in Melanoma Gene Location Clinical/Histologic Characteristics BRAF 7q34 * Most common alteration in melanoma * Often sites of acute intermittent sun exposure (superficial spreading, nodular melanomas) GNAQ and GNA11 9q21, 19p13 * Uveal melanoma * Blue nevi KIT 4q11-12 * Mucosal melanoma * Acral melanoma * Some melanomas in chronically sun- damaged skin (some lentigo maligna melanomas) NRAS 1p13 * BRAF-wild-type melanomas * More nodular melanomas, but also superficial spreading * Slight relative increase in extremity location RET 10q11 * Desmoplastic melanoma * Lower frequency in cutaneous nondesmoplastic melanoma Gene Gene Function BRAF * Proto-oncogene in Ras-Raf-MAPK cascade * Activates MEK GNAQ and GNA11 * Proto-oncogenes * Guanine nucleotide-binding proteins KIT * Proto-oncogene * Receptor tyrosine kinase for stem cell factor * Broad effect on downstream pathways NRAS * Proto-oncogene in Ras-Raf-MAPK cascade RET * Proto-oncogene * Receptor tryosine kinase * Bound by glial cell line-derived neutrotrophic factor Gene Common Genetic Abnormalities BRAF Point mutation leading to V599E substitution in activation segment; leads to increased enzymatic activity GNAQ and GNA11 Mutations in codons 183 and 209 lead to constitutive activation KIT Mutations in region coding for juxtamembrane domain; constitutive activation of kinase NRAS Activating mutations in codon 61 RET Polymorphism (G691S) leads to increased downstream activity of MAPK and PI3K/Akt pathways Abbreviations: MAPK, mitogen-activated protein (MAP) kinase; MEK, MAP kinase kinase; PI3K, phosphoinositide-3 kinase.
|Printer friendly Cite/link Email Feedback|
|Author:||Kraft, Stefan; Granter, Scott R.|
|Publication:||Archives of Pathology & Laboratory Medicine|
|Date:||Jun 1, 2014|
|Previous Article:||Utility of Repeat Testing of Critical Values: A Q-Probes Analysis of 86 Clinical Laboratories.|
|Next Article:||Loss of Heterozygosity and Microsatellite Instability Are Rare in Sporadic Dedifferentiated Liposarcoma: A Study of 43 Well-Characterized Cases.|